<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients - Cortegiani, A - 2016 | Cochrane Library</title> <meta content="Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients - Cortegiani, A - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004920.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients - Cortegiani, A - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004920.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004920.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients" name="citation_title"/> <meta content="Andrea Cortegiani" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="andreacortegiani85@gmail.com" name="citation_author_email"/> <meta content="Vincenzo Russotto" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="Alessandra Maggiore" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="Massimo Attanasio" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="Alessandro R Naro" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="Santi Maurizio Raineri" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="Antonino Giarratano" name="citation_author"/> <meta content="University of Palermo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD004920.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/01/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004920.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004920.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004920.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amphotericin B [therapeutic use]; Antifungal Agents [*therapeutic use]; Critical Illness [*mortality]; Fluconazole [therapeutic use]; Immunocompromised Host; Mycoses [mortality, *prevention &amp; control]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004920.pub3&amp;doi=10.1002/14651858.CD004920.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004920\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004920\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004920.pub3",title:"Antifungal agents for preventing fungal infections in non\\u2010neutropenic critically ill patients",firstPublishedDate:"Jan 16, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Emergency and Critical Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004920.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004920.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004920.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004920.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004920.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004920.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004920.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004920.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004920.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004920.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4419 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004920.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/appendices#CD004920-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/table_n/CD004920StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/table_n/CD004920StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Andrea Cortegiani</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0003">Vincenzo Russotto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0004">Alessandra Maggiore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0005">Massimo Attanasio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0006">Alessandro R Naro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0007">Santi Maurizio Raineri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information#CD004920-cr-0008">Antonino Giarratano</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information/en#CD004920-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 January 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004920.pub3">https://doi.org/10.1002/14651858.CD004920.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004920-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004920-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004920-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004920-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004920-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004920-abs-0001" lang="en"> <section id="CD004920-sec-0001"> <h3 class="title" id="CD004920-sec-0001">Background</h3> <p>Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with suspicion of fungal infection in critically ill, non‐neutropenic patients, taking into account recent findings in this field. </p> </section> <section id="CD004920-sec-0002"> <h3 class="title" id="CD004920-sec-0002">Objectives</h3> <p>To assess the effects of untargeted treatment with any antifungal drug (either systemic or nonabsorbable) compared to placebo or no antifungal or any other antifungal drug (either systemic or nonabsorbable) in non‐neutropenic, critically ill adults and children. We assessed effectiveness in terms of total (all‐cause) mortality and incidence of proven invasive fungal infections as primary outcomes. </p> </section> <section id="CD004920-sec-0003"> <h3 class="title" id="CD004920-sec-0003">Search methods</h3> <p> We searched the following databases to February 2015: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID), and EMBASE (OVID). We also searched reference lists of identified studies and major reviews, abstracts of conference proceedings, scientific meetings and clinical trials registries. We contacted experts in the field, study authors and pharmaceutical companies as part of the search strategy. </p> </section> <section id="CD004920-sec-0004"> <h3 class="title" id="CD004920-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) (irrespective of language or publication status) comparing the use of untargeted treatment with any antifungal drug (either systemic or nonabsorbable) to placebo, no antifungal, or another antifungal agent in non‐neutropenic critically ill participants. </p> </section> <section id="CD004920-sec-0005"> <h3 class="title" id="CD004920-sec-0005">Data collection and analysis</h3> <p>Three authors independently applied selection criteria, extracted data and assessed the risk of bias. We resolved any discrepancies by discussion. We synthesized data using the random‐effects model and expressed the results as risk ratios (RR) with 95% confidence intervals. We assessed overall evidence quality using the GRADE approach. </p> </section> <section id="CD004920-sec-0006"> <h3 class="title" id="CD004920-sec-0006">Main results</h3> <p>We included 22 studies (total of 2761 participants). Of those 22 studies, 12 were included in the original published review and 10 were newly identified. Eleven trials compared the use of fluconazole to placebo or no antifungal treatment. Three trials compared ketoconazole versus placebo. One trial compared anidulafungin with placebo. One trial compared caspofungin to placebo. Two trials compared micafungin to placebo. One trial compared amphotericin B to placebo. Two trials compared nystatin to placebo and one trial compared the effect of clotrimazole, ketoconazole, nystatin and no treatment. We found two new ongoing studies and four new studies awaiting classification. The RCTs included participants of both genders with wide age range, severity of critical illness and clinical characteristics. Funding sources from pharmaceutical companies were reported in 11 trials and one trial reported funding from a government agency. Most of the studies had an overall unclear risk of bias for key domains of this review (random sequence generation, allocation concealment, incomplete outcome data). Two studies had a high risk of bias for key domains. Regarding the other domains (blinding of participants and personnel, outcome assessment, selective reporting, other bias), most of the studies had a low or unclear risk but four studies had a high risk of bias. </p> <p>There was moderate grade evidence that untargeted antifungal treatment did not significantly reduce or increase total (all‐cause) mortality (RR 0.93, 95% CI 0.79 to 1.09, P value = 0.36; participants = 2374; studies = 19). With regard to the outcome of proven invasive fungal infection, there was low grade evidence that untargeted antifungal treatment significantly reduced the risk (RR 0.57, 95% CI 0.39 to 0.83, P value = 0.0001; participants = 2024; studies = 17). The risk of fungal colonization was significantly reduced (RR 0.71, 95% CI 0.52 to 0.97, P value = 0.03; participants = 1030; studies = 12) but the quality of evidence was low. There was no difference in the risk of developing superficial fungal infection (RR 0.69, 95% CI 0.37 to 1.29, P value = 0.24; participants = 662; studies = 5; low grade of evidence) or in adverse events requiring cessation of treatment between the untargeted treatment group and the other group (RR 0.89, 95% CI 0.62 to 1.27, P value = 0.51; participants = 1691; studies = 11; low quality of evidence). The quality of evidence for the outcome of total (all‐cause) mortality was moderate due to limitations in study design. The quality of evidence for the outcome of invasive fungal infection, superficial fungal infection, fungal colonization and adverse events requiring cessation of therapy was low due to limitations in study design, non‐optimal total population size, risk of publication bias, and heterogeneity across studies. </p> </section> <section id="CD004920-sec-0007"> <h3 class="title" id="CD004920-sec-0007">Authors' conclusions</h3> <p>There is moderate quality evidence that the use of untargeted antifungal treatment is not associated with a significant reduction in total (all‐cause) mortality among critically ill, non‐neutropenic adults and children compared to no antifungal treatment or placebo. The untargeted antifungal treatment may be associated with a reduction of invasive fungal infections but the quality of evidence is low, and both the heterogeneity and risk of publication bias is high. </p> <p>Further high‐quality RCTs are needed to improve the strength of the evidence, especially for more recent and less studied drugs (e.g. echinocandins). Future trials should adopt standardized definitions for microbiological outcomes (e.g. invasive fungal infection, colonization) to reduce heterogeneity. Emergence of resistance to antifungal drugs should be considered as outcome in studies investigating the effects of untargeted antifungal treatment to balance risks and benefit. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004920-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004920-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD004920-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD004920-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004920-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004920-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD004920-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004920-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004920-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004920-abs-0004" lang="en"> <h3>Antifungal agents for preventing fungal infections in critically ill adults and children with a normal number of neutrophils in the blood </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of giving antifungal medications before a definitive diagnosis of fungal infections on mortality from all causes and development of severe infections due to fungi (invasive fungal infections) in adults and children who are critically ill but non‐neutropenic, i.e. with a normal number of neutrophils in their blood. </p> <p><b>Background</b> </p> <p>Critically ill adults and children may suffer from invasive fungal infections, such as those affecting the bloodstream and other organs. Once established, such infections are difficult to treat and frequently result in death. Antifungal medications are sometimes given to critically ill adults and children most prone to developing fungal infections and to those with signs of infections when it is still unclear if a fungus is the cause. </p> <p><b>Study characteristics</b> </p> <p>We included 22 randomized controlled trials (RCTs) (total of 2761 participants). Eleven trials compared the use of fluconazole to placebo or no antifungal treatment. Three trials compared ketoconazole versus placebo. One trial compared anidulafungin with placebo. One trial compared caspofungin to placebo. Two trials compared micafungin to placebo. One trial compared amphotericin B to placebo. Two trials compared nystatin to placebo and one trial compared the effect of clotrimazole, ketoconazole, nystatin and no treatment. The RCTs included participants of both genders with a wide age range and severity of critical illness. </p> <p><b>Search date</b> </p> <p>The evidence is current as of February 2015.</p> <p><b>Study funding sources</b> </p> <p>Funding sources from drug manufacturers were reported in 11 out of 22 studies. Another study was funded by a government agency. </p> <p><b>Key results</b> </p> <p>Results of 19 from 22 randomized trials involved 2374 participants and showed that antifungal medications given before definitive diagnosis of fungal infection did not reduce mortality from all causes. None of the studied drugs were associated with a significant reduction of mortality from all causes. However, results from 17 randomized studies involving 2024 participants showed that antifungal drugs significantly reduced the risk of developing invasive fungal infections. </p> <p>We also reviewed the evidence from five trials (662 participants) about the effect of antifungal treatment on the development of superficial fungal infections but we did not find any significant difference. However, we found evidence from 12 trials (1020 participants) of a significant reduction of fungi in body sites (excluding blood) not causing an infection. Eleven trials (1691 participants) reported serious adverse events requiring cessation of therapy. We found no evidence of differences in serious adverse events requiring interruption of antifungal medications between people who received and those who did not receive them. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence for the outcome of mortality (all‐cause) was moderate due to limitations in study design. The quality of evidence for the outcome of invasive fungal infection, superficial fungal infection, fungal colonization and adverse events requiring cessation of therapy was low due to limitations in study design, non‐optimal total number of patients studied and results inconsistent across studies. </p> <p><b>Conclusion</b> </p> <p>There is moderate quality evidence that the use of antifungal treatment given before definitive diagnosis of fungal infection is not associated with a significant reduction in mortality from all causes among critically ill adults and children with a normal number of neutrophils in the blood. This type of antifungal treatment may be associated with a reduction of invasive fungal infections but the quality of evidence on this point is low. </p> <p>Further studies with high‐quality design are needed to improve the evidence.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004920-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004920-sec-0086"></div> <h3 class="title" id="CD004920-sec-0087">Implications for practice</h3> <section id="CD004920-sec-0087"> <p>At present, in critically ill, non‐neutropenic patients, there is moderate‐quality evidence that un‐targeted treatment with any antifungal drug does not significantly increase or reduce total (all‐cause) mortality. There is low‐grade evidence supporting the use of untargeted antifungal treatment for prevention of invasive fungal infection. The reduction of invasive fungal infections is observed when fluconazole and caspofungin are used as antifungal medication. Low‐quality evidence supports the efficacy of the intervention for fungal colonization reduction. The use of untargeted antifungal drugs does not seem to be associated with an increase of superficial fungal infections and adverse events requiring cessation of treatment with low quality of evidence for both outcomes. The clinical decision of starting an untargeted antifungal treatment in non‐neutropenic critically ill patients should consider patients' characteristics, type of drugs available and feasible type of antifungal strategy (i.e. prophylactic, pre‐emptive and empiric). </p> </section> <h3 class="title" id="CD004920-sec-0088">Implications for research</h3> <section id="CD004920-sec-0088"> <p>The evidence provided by this updated review on the effect of untargeted antifungal treatment is not conclusive. Further research may be justified focusing on which specific untargeted antifungal treatment among prophylactic, pre‐emptive and empiric is most beneficial in non‐neutropenic, critically ill patients. Further high‐quality randomized controlled trials should be done to investigate the use of drugs less studied in this setting to date. Two ongoing trials are addressing some of these issues, giving more evidence in the next future (<a href="./references#CD004920-bbs2-0045" title="EudraCT number:2012‐003172‐39 . Micafungin‐Deescalation study: Evalutating the rate of breakthrough infections of micafungin followed by fluconazole versus fluconazole (or other azoles) in febrile patients. www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐003172‐39/AT2013. ">Lass‐Flörl 2013</a>; <a href="./references#CD004920-bbs2-0046" title="NCT01773876 . Empirical Antifungal Treatment in ICUS (EMPIRICUS). clinicaltrials.gov/ct2/show/NCT017738762012. TimsitJF , AzoulayE , CornetM , GangneuxJP , JullienV , VésinA , et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi‐colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials2013;14:399. [PUBMED: 24261608] ">Timsit 2012</a>). </p> <p>Future trials should adopt standardized definitions of microbiological outcomes (e.g. invasive fungal infection, fungal colonization) to reduce heterogeneity. Moreover, they should consider the emergence of resistance to antifungal drugs, especially with the use of recently introduced compounds (e.g. echinocandins), to balance risks and benefit of untargeted antifungal treatment . </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004920-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004920-sec-0022"></div> <div class="table" id="CD004920-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal in non‐neutropenic critically ill patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Any untargeted treatment with antifungal drugs (systemic or nonabsorbable) compared to placebo, no antifungal, any other antifungal compared to placebo for preventing fungal infections in non‐neutropenic critically ill patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preventing fungal infections in non‐neutropenic critically ill patients<br/> <b>Settings: c</b> ritical care setting<br/> <b>Intervention:</b> untargeted treatment with any antifungal drug (systemic or nonabsorbable)<br/> <b>Comparison:</b> placebo or no antifungal or any other antifungal </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no antifungal or any other antifungal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Untargeted treatment with any antifungal drug (systemic or nonabsorbable)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total (all‐cause) mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.93<br/> (0.79 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2374<br/> (19 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000<br/> (193 to 266) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/> (163 to 226) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Proven invasive fungal infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.57<br/> (0.39 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2024<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/> (40 to 86) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (10 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Superficial fungal infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.69<br/> (0.37 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>662<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (26 to 90) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (11 to 40) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Fungal colonization</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.71<br/> (0.52 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1030<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>279 per 1000<br/> (204 to 381) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000<br/> (97 to 181) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events requiring cessation of study drug(s)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.89<br/> (0.62 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1691<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (43 to 88) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (72 to 148) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Most of studies that contributed to this result had an unclear risk of bias. Downgraded by one level. </p> <p><sup>2</sup>Asymmetry of the funnel plot detected by observation. Downgraded by one level. </p> <p><sup>3</sup>All the five studies that contributed to this result had an unclear risk of bias. Downgraded by one level. </p> <p><sup>4</sup>Total number of patients and events from studies that contributed to this result was less than the number of patients generated for the calculation of optimal information size. Downgraded by one level. </p> <p><sup>5</sup>All the studies that contributed to this result had an unclear risk of bias. Downgraded by one level. </p> <p><sup>6</sup>There was considerable statistical heterogeneity across studies. The use of different criteria for detection of fungal colonization in studies contributing to this result may have led to clinical heterogeneity. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004920-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004920-sec-0023"></div> <section id="CD004920-sec-0024"> <h3 class="title" id="CD004920-sec-0024">Description of the condition</h3> <p>Invasive fungal infections (IFIs) are a well‐documented complication of critically ill patients. Patients in an intensive care unit (ICU) have different risk factors for fungal infections development, including broad spectrum antibiotic therapy, disruption of natural barriers due to surgery or implantation of invasive devices (for treatment or monitoring), fungal colonization, impairment of immunological response (<a href="./references#CD004920-bbs2-0065" title="HermsenED , ZapapasMK , MaiefskiM , RuppME , FreifeldAG , KalilAC . Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case‐control study. Critical Care2011;15:R198. [PUBMED: 21846332] ">Hermsen 2011</a>; <a href="./references#CD004920-bbs2-0081" title="Ostrosky‐ZeichnerL , SableC , SobelJ , AlexanderBD , DonowitzG , KanV , et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. European Journal of Clinical Microbiology and Infectious Diseases2007;26(4):271‐6. [PUBMED: 17333081] ">Ostrosky‐Zeichner 2007</a>). IFIs are a major cause of morbidity and mortality among critically ill patients. According to different studies, attributable mortality due to <i>Candida spp</i>. infections ranges from about 42% to about 63% (<a href="./references#CD004920-bbs2-0071" title="KettDH , AzoulayE , EcheverriaPM , VincentJL , EPIC II Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Critical Care Medicine2011;39(4):665‐70. [PUBMED: 21169817] ">Kett 2011</a>; <a href="./references#CD004920-bbs2-0072" title="KollefM , MicekS , HamptonN , DohertyJA , KumarA . Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clinical Infectious Diseases2012;54(12):1740‐6. [PUBMED: 22423135] ">Kollef 2012</a>; <a href="./references#CD004920-bbs2-0088" title="Puig‐AsensioM , PadillaB , Garnacho‐MonteroJ , ZaragozaO , AguadoJM , ZaragozaR , et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population‐based surveillance in Spain. Clinical Microbiology and Infection2014;20(4):O245‐54. [PUBMED: 24125548] ">Puig‐Asensio 2014a</a>). Moreover, IFIs impose an important economic burden mainly due to prolonged ICU stay, cost of antifungal drugs and overall use of hospital resources (<a href="./references#CD004920-bbs2-0058" title="Dodds AshleyE , DrewR , JohnsonM , DannaR , DabrowskiD , WalkerV , et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy2012;32(10):890‐901. [PUBMED: 23033228] ">Dodds Ashley 2012</a>; <a href="./references#CD004920-bbs2-0064" title="HassanI , PowellG , SidhuM , HartWM , DenningDW . Excess mortality, length of stay and cost attributable to candidaemia. Journal of Infection2009;59(5):360‐5. [PUBMED: 19744519 ] ">Hassan 2009</a>; <a href="./references#CD004920-bbs2-0090" title="RentzAM , HalpernMT , BowdenR . The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clinical Infectious Diseases1998;27(4):781‐8. [MEDLINE: 9798034] ">Rentz 1998</a>). Bloodstream infection (BSI) due to <i>Candida spp</i>. (candidaemia) is considered the most common IFI in critically ill patients (<a href="./references#CD004920-bbs2-0050" title="BassettiM , RighiE , AnsaldiF , MerelliM , ScarpatoC , AntonelliM , et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine2015;41(9):1601‐10. [PUBMED: 26077063] ">Bassetti 2015</a>; <a href="./references#CD004920-bbs2-0071" title="KettDH , AzoulayE , EcheverriaPM , VincentJL , EPIC II Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Critical Care Medicine2011;39(4):665‐70. [PUBMED: 21169817] ">Kett 2011</a>; <a href="./references#CD004920-bbs2-0073" title="KullbergBJ , ArendrupMC . Invasive Candidiasis. New England Journal of Medicine2015;373(15):1445‐56. [PUBMED: 26444731] ">Kullberg 2015</a>; <a href="./references#CD004920-bbs2-0098" title="VincentJL , RelloJ , MarshallJ , SilvaE , AnzuetoA , MartinCD , et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA2009;302(21):2323‐9. [PUBMED: 19952319] ">Vincent 2009</a>). In specific subgroups of patients (e.g. abdominal surgical patients), other forms of IFIs are also frequent (e.g. intra‐abdominal candidiasis), alone or in combination with candidaemia (<a href="./references#CD004920-bbs2-0049" title="BassettiM , MarchettiM , ChakrabartiA , ColizzaS , Garnacho‐MonteroJ , KettDH , et al. A research agenda on the management of intra‐abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine2013;39(12):2092‐106. [PUBMED: 24105327] ">Bassetti 2013</a>; <a href="./references#CD004920-bbs2-0050" title="BassettiM , RighiE , AnsaldiF , MerelliM , ScarpatoC , AntonelliM , et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine2015;41(9):1601‐10. [PUBMED: 26077063] ">Bassetti 2015</a>). Among fungal pathogens, <i>Candida spp</i>. are the most commonly isolated microorganisms, currently ranking the fourth most commonly identified pathogens in nosocomial BSIs and the third most common pathogens isolated in ICU patients (<a href="./references#CD004920-bbs2-0098" title="VincentJL , RelloJ , MarshallJ , SilvaE , AnzuetoA , MartinCD , et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA2009;302(21):2323‐9. [PUBMED: 19952319] ">Vincent 2009</a>; <a href="./references#CD004920-bbs2-0099" title="WisplinghoffH , BischoffT , TallentSM , SeifertH , WenzelRP , EdmondMB . Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases2004;39(3):309‐17. [PUBMED: 15306996] ">Wisplinghoff 2004</a>). A prompt, effective antifungal treatment is one of the most important determinants for mortality reduction, especially in patients with septic shock attributed to <i>Candida</i> infections (<a href="./references#CD004920-bbs2-0061" title="GareyKW , RegeM , PaiMP , MingoDE , SudaKJ , TurpinRS , et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi‐institutional study. Clinical Infectious Diseases2006;43(1):25‐31. ">Garey 2006</a>; <a href="./references#CD004920-bbs2-0072" title="KollefM , MicekS , HamptonN , DohertyJA , KumarA . Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clinical Infectious Diseases2012;54(12):1740‐6. [PUBMED: 22423135] ">Kollef 2012</a>; <a href="./references#CD004920-bbs2-0080" title="MatthewM , FraserVJ , KollefMH . Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy2005;49(9):3640‐5. [PUBMED: 16127033] ">Morrell 2005</a>; <a href="./references#CD004920-bbs2-0089" title="Puig‐AsensioM , PemánJ , ZaragozaR , Garnacho‐MonteroJ , Martín‐MazuelosE , Cuenca‐EstrellaM , et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Critical Care Medicine2014;42(6):1423‐32. [PUBMED: 24557426] ">Puig‐Asensio 2014b</a>). </p> </section> <section id="CD004920-sec-0025"> <h3 class="title" id="CD004920-sec-0025">Description of the intervention</h3> <p>The administration of an antifungal drug after the definitive microbiological proof of fungal infection constitutes what has been defined as targeted antifungal therapy. Due to the long turnaround time for culture results with late microbiological documentation in the course of infections (<a href="./references#CD004920-bbs2-0049" title="BassettiM , MarchettiM , ChakrabartiA , ColizzaS , Garnacho‐MonteroJ , KettDH , et al. A research agenda on the management of intra‐abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine2013;39(12):2092‐106. [PUBMED: 24105327] ">Bassetti 2013</a>; <a href="./references#CD004920-bbs2-0056" title="Cuenca‐EstrellaM , VerweijPE , ArendrupMC , Arikan‐AkdagliS , BilleJ , DonnellyJP , et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection2012;18(Suppl 7):9‐18. [PUBMED: 23137134] ">Cuenca‐Estrella 2012</a>; <a href="./references#CD004920-bbs2-0060" title="FernandezJ , ErstadBL , PettyW , NixDE . Time to positive culture and identification for Candida blood stream infections. Diagnostic Microbiology and Infectious Disease2009;64(4):402‐7. [PUBMED: 19446982] ">Fernandez 2011</a>), and the increasing mortality associated with a delay in therapy institution (<a href="./references#CD004920-bbs2-0061" title="GareyKW , RegeM , PaiMP , MingoDE , SudaKJ , TurpinRS , et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi‐institutional study. Clinical Infectious Diseases2006;43(1):25‐31. ">Garey 2006</a>; <a href="./references#CD004920-bbs2-0072" title="KollefM , MicekS , HamptonN , DohertyJA , KumarA . Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clinical Infectious Diseases2012;54(12):1740‐6. [PUBMED: 22423135] ">Kollef 2012</a>, <a href="./references#CD004920-bbs2-0080" title="MatthewM , FraserVJ , KollefMH . Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy2005;49(9):3640‐5. [PUBMED: 16127033] ">Morrell 2005</a>; <a href="./references#CD004920-bbs2-0089" title="Puig‐AsensioM , PemánJ , ZaragozaR , Garnacho‐MonteroJ , Martín‐MazuelosE , Cuenca‐EstrellaM , et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Critical Care Medicine2014;42(6):1423‐32. [PUBMED: 24557426] ">Puig‐Asensio 2014b</a>), different antifungal strategies have been studied for preventing IFI in non‐neutropenic critically ill patients. The administration of any antifungal drug prior to the definitive microbiological evidence of fungal infection constitutes an untargeted antifungal treatment . Recently, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) provided the definitions of three different treatment strategies, classifying them into prophylactic, pre‐emptive and empiric treatments (<a href="./references#CD004920-bbs2-0053" title="CornelyOA , BassettiM , CalandraT , GarbinoJ , KullbergBJ , LortholaryO . ESCMID guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. Clinical Microbiology and Infection2012;18 Suppl 7:19‐37. [PUBMED: 23137135] ">Cornely 2012</a>). Prophylaxis has been defined as the administration of antifungal agents in patients without proven or suspected fungal infection (i.e. absence of microbiological or radiological evidence) but with risk factors for its development (e.g. patients treated with broad spectrum antibiotics, presence of a central venous catheter, under parenteral nutrition or who underwent major abdominal surgery). Pre‐emptive treatment (<i>diagnosis‐driven approach</i>) has been defined as treatment triggered by microbiological evidence of fungal infection, without definitive microbiological proof. Surrogate biomarkers for the presence of fungal infection (e.g. 1‐3 ß‐D‐glucan, mannan/anti‐mannan antibody) have been investigated for this purpose (<a href="./references#CD004920-bbs2-0079" title="MikulskaM , CalandraT , SanguinettiM , PoulainD , ViscoliC , the Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti‐mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Critical Care2010;14:R222. [PUBMED: 21143834] ">Mikulska 2010</a>; <a href="./references#CD004920-bbs2-0087" title="PosteraroB , DePascaleG , TumbarelloM , TorelliR , PennisiMA , BelloG , et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1‐3)‐b‐D‐glucan assay, Candida score, and colonization index. Critical Care2011;15:R249. [PUBMED: 22018278] ">Posteraro 2011</a>). Empiric treatment (<i>fever‐driven approach</i>) has been defined as the antifungal treatment triggered by signs and symptoms of infection in patients at risk for IFI, in the absence of microbiological evidence of infection at the moment of therapy institution. </p> </section> <section id="CD004920-sec-0026"> <h3 class="title" id="CD004920-sec-0026">How the intervention might work</h3> <p>A prompt effective antifungal treatment is one of the most important determinants for mortality reduction in patients with severe sepsis or septic shock due to fungal infections. Unfortunately, despite advances in microbiological techniques, the proven diagnosis of fungal infections requires several days and usually occurs late (<a href="./references#CD004920-bbs2-0049" title="BassettiM , MarchettiM , ChakrabartiA , ColizzaS , Garnacho‐MonteroJ , KettDH , et al. A research agenda on the management of intra‐abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine2013;39(12):2092‐106. [PUBMED: 24105327] ">Bassetti 2013</a>; <a href="./references#CD004920-bbs2-0056" title="Cuenca‐EstrellaM , VerweijPE , ArendrupMC , Arikan‐AkdagliS , BilleJ , DonnellyJP , et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection2012;18(Suppl 7):9‐18. [PUBMED: 23137134] ">Cuenca‐Estrella 2012</a>; <a href="./references#CD004920-bbs2-0060" title="FernandezJ , ErstadBL , PettyW , NixDE . Time to positive culture and identification for Candida blood stream infections. Diagnostic Microbiology and Infectious Disease2009;64(4):402‐7. [PUBMED: 19446982] ">Fernandez 2011</a>). The advantage of antifungal treatment given before definitive microbiological diagnosis has been established in high‐risk patients such as cancer patients and solid organ transplant recipients (<a href="./references#CD004920-bbs2-0055" title="CrucianiM , MengoliC , MalenaM , BoscoO , SerpelloniG , GrossiP . Antifungal prophylaxis in liver transplant patients: a systematic review and meta‐analysis. Liver Transplantation2006;12(5):850‐8. [PUBMED: 16628697] ">Cruciani 2006</a>; <a href="./references#CD004920-bbs2-0063" title="GøtzschePC , JohansenHK . Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD000026.pub2] ">Gøtzsche 2014</a>; <a href="./references#CD004920-bbs2-0076" title="MarinoE , GallagherJC . Prophylactic antifungal agents used after lung transplantation. The Annals of Pharmacotherapy2010;44(3):546‐56. [PUBMED: 20179260] ">Marino 2010</a>; <a href="./references#CD004920-bbs2-0086" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004291.pub2] ">Playford 2004a</a>). In these populations, the use of antifungal agents has been proven to be effective for IFI reduction. However, in non‐neutropenic critically ill patients, several antifungal strategies have been investigated among different selected populations (e.g. surgical or nonsurgical patients). In non‐neutropenic critically ill patients, the definitive evidence for the effect on mortality and IFIs by untargeted treatment has not been established to date. Potential detrimental effects of the extensive use of antifungal agents are the emergence of <i>Candida spp</i>. with reduced susceptibility to drugs (<a href="./references#CD004920-bbs2-0059" title="FekkarA , DannaouiE , MeyerI , ImbertS , BrossasJY , UzunovM , et al. Emergence of echinocandin‐resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?. European Journal of Clinical Microbiology &amp; Infectious Diseases2014;33(9):1489‐96. [PUBMED: 24715154] ">Fekkar 2014</a>; <a href="./references#CD004920-bbs2-0083" title="PfallerMA . Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. The American Journal of Medicine2012;125(1):S2‐S13. [PUBMED: 22196207] ">Pfaller 2012</a>), drug‐induced side effects and an increase of financial costs (<a href="./references#CD004920-bbs2-0075" title="LortholaryO , Desnos‐OllivierM , SitbonK , FontanetA , BretagneS , DromerF , et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.. Antimicrobial Agents and Chemotherapy2011;55(2):532‐8. [PUBMED: 21078946] ">Lortholary 2011</a>). </p> </section> <section id="CD004920-sec-0027"> <h3 class="title" id="CD004920-sec-0027">Why it is important to do this review</h3> <p>Antifungal drugs given to critically ill patients before definitive microbiological proof of IFIs may have a positive impact on patients' outcome given the high morbidity and mortality, especially in case of inadequate and late antifungal treatment (<a href="./references#CD004920-bbs2-0061" title="GareyKW , RegeM , PaiMP , MingoDE , SudaKJ , TurpinRS , et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi‐institutional study. Clinical Infectious Diseases2006;43(1):25‐31. ">Garey 2006</a>; <a href="./references#CD004920-bbs2-0072" title="KollefM , MicekS , HamptonN , DohertyJA , KumarA . Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clinical Infectious Diseases2012;54(12):1740‐6. [PUBMED: 22423135] ">Kollef 2012</a>; <a href="./references#CD004920-bbs2-0080" title="MatthewM , FraserVJ , KollefMH . Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy2005;49(9):3640‐5. [PUBMED: 16127033] ">Morrell 2005</a>; <a href="./references#CD004920-bbs2-0089" title="Puig‐AsensioM , PemánJ , ZaragozaR , Garnacho‐MonteroJ , Martín‐MazuelosE , Cuenca‐EstrellaM , et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Critical Care Medicine2014;42(6):1423‐32. [PUBMED: 24557426] ">Puig‐Asensio 2014b</a>). The original review aimed to determine the benefits and harms of the prophylactic administration of antifungals in non‐neutropenic, critically ill patients. That review incorporated the existing evidence up to 2005 (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>). During these last 10 years, the administration of antifungal drugs for prevention of fungal infections has been further investigated, additional antifungal treatments have been introduced for this purpose and the role of colonization for subsequent development of fungal infection has been better clarified (<a href="./references#CD004920-bbs2-0074" title="LauAF , KabirM , ChenSC , PlayfordEG , MarriotDJ , et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical‐surgical intensive care units: development and evaluation of a simple, standard protocol. Journal of Clinical Microbiology2015;54(4):1324‐30. [PUBMED: 25673797] ">Lau 2015</a>; <a href="./references#CD004920-bbs2-0085" title="PittetD , MonodM , SuterPM , FrenkE , AuckenthalerR . Candida colonisation and subsequent infections in critically ill surgical patients. Annals of Surgery1994;220(6):751‐8. [MEDLINE: 7986142] ">Pittet 1994</a>; <a href="./references#CD004920-bbs2-0097" title="VardakasKZ , MichalopoulosA , KiriakidouKG , SiampliEP , SamonisG , FalagasME . Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients. Clinical Microbiology and Infection2009;15(3):289‐92. [PUBMED: 19154488] ">Vardakas 2009</a>). This updated version was conducted to determine the current state of the evidence in this regard. Recently, different approaches for fungal infection prevention and treatment have been better defined and standardized by international guidelines (<a href="./references#CD004920-bbs2-0053" title="CornelyOA , BassettiM , CalandraT , GarbinoJ , KullbergBJ , LortholaryO . ESCMID guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. Clinical Microbiology and Infection2012;18 Suppl 7:19‐37. [PUBMED: 23137135] ">Cornely 2012</a>). In the original review, authors used "antifungal prophylaxis" as a definition for the intervention encompassing the terms prophylaxis, pre‐emptive and empiric treatments (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>). In order to avoid confusion and considering the new definitions, in this updated version we decided to use the term "untargeted treatment" to identify the use of any antifungal agent given prior to the definitive microbiological diagnosis. "Un‐targeted treatment" encompasses the terms prophylaxis, pre‐emptive and empiric treatments. Recent evidence reconsidered the role of <i>Candida spp</i>. detection from respiratory tract specimens (<a href="./references#CD004920-bbs2-0078" title="MeerssemanW , LagrouK , SprietI , MaertensJ , VerbekenE , PeetermansWE , et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Medicine2009;35(9):1526‐31. [PUBMED: 19357832] ">Meerssemann 2009</a>), leading to the suggestion by international guidelines of considering this event a colonization rather than invasive infection (<a href="./references#CD004920-bbs2-0053" title="CornelyOA , BassettiM , CalandraT , GarbinoJ , KullbergBJ , LortholaryO . ESCMID guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. Clinical Microbiology and Infection2012;18 Suppl 7:19‐37. [PUBMED: 23137135] ">Cornely 2012</a>). Consequently, we modified the definition of a primary outcome (invasive fungal infection), excluding those events involving the respiratory tract. In older studies, azole antifungals (e.g. fluconazole, ketoconazole) were more commonly used for this purpose. Recently, another class of antifungal agents, namely echinocandins (e.g. anidulafungin, caspofungin, micafungin) have been introduced for both targeted and untargeted treatment use in a broad spectrum of clinical conditions including critically ill, non‐neutropenic patients. Moreover, since <i>Candida</i> colonization has been identified as a risk factor for subsequent IFI (<a href="./references#CD004920-bbs2-0074" title="LauAF , KabirM , ChenSC , PlayfordEG , MarriotDJ , et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical‐surgical intensive care units: development and evaluation of a simple, standard protocol. Journal of Clinical Microbiology2015;54(4):1324‐30. [PUBMED: 25673797] ">Lau 2015</a>; <a href="./references#CD004920-bbs2-0085" title="PittetD , MonodM , SuterPM , FrenkE , AuckenthalerR . Candida colonisation and subsequent infections in critically ill surgical patients. Annals of Surgery1994;220(6):751‐8. [MEDLINE: 7986142] ">Pittet 1994</a>; <a href="./references#CD004920-bbs2-0097" title="VardakasKZ , MichalopoulosA , KiriakidouKG , SiampliEP , SamonisG , FalagasME . Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients. Clinical Microbiology and Infection2009;15(3):289‐92. [PUBMED: 19154488] ">Vardakas 2009</a>), nonabsorbable antifungal drugs (e.g. nystatin) have been studied for its prevention. For this reason, we studied these types of antifungal drugs as part of the intervention of interest for this updated review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004920-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004920-sec-0028"></div> <p>To assess the effects of untargeted treatment with any antifungal drug (either systemic or nonabsorbable) compared to placebo or no antifungal or any other antifungal drug (either systemic or nonabsorbable) in non‐neutropenic critically ill adults and children. We assessed effectiveness in terms of mortality and incidence of proven invasive fungal infections as primary outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004920-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004920-sec-0029"></div> <section id="CD004920-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004920-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered all randomized controlled trials (RCTs) that evaluated the effect of any antifungal agent given as untargeted treatment in non‐neutropenic critically ill adults and children. </p> </section> <section id="CD004920-sec-0032"> <h4 class="title">Types of participants</h4> <p>We considered trials involving adult participants (aged 18 years or over) and children (aged less than 18 years), classified as critically ill (such as those admitted to an ICU or having recently undergone an abdominal or other major surgical procedure). </p> <p>We excluded trials involving neutropenic, neonatal or HIV‐infected participants, participants predominantly with malignancies or solid organ transplant recipients, as systematic reviews have been published for these patient groups (<a href="./references#CD004920-bbs2-0047" title="AustinN , McGuideW . Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003850.pub4] ">Austin 2013a</a>; <a href="./references#CD004920-bbs2-0048" title="AustinN , DarlowBA , McGuireW . Prophylactic oral/topical non‐absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD003478.pub4] ">Austin 2013b</a>; <a href="./references#CD004920-bbs2-0063" title="GøtzschePC , JohansenHK . Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD000026.pub2] ">Gøtzsche 2014</a>). </p> <p>We included trials including non‐neutropenic critically ill participants along with other groups if the proportion of these was less than 25% or if data on non‐neutropenic patients were separately provided. </p> </section> <section id="CD004920-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We considered trials if they involved the randomized comparison of any antifungal drug (either systemic or nonabsorbable) with placebo, no antifungal or any other antifungal drug (either systemic or nonabsorbable). </p> <p>We included studies in which antifungal drugs were initiated before microbiological definitive evidence of infection (untargeted approach, encompassing the prophylactic, pre‐emptive and empiric treatment). </p> <p>We decided to consider an eligible intervention the administration of untargeted treatment with nonabsorbable antifungals since colonization has been described as a risk factor for subsequent development of IFIs (<a href="./references#CD004920-bbs2-0074" title="LauAF , KabirM , ChenSC , PlayfordEG , MarriotDJ , et al. Candida colonization as a risk marker for invasive candidiasis in mixed medical‐surgical intensive care units: development and evaluation of a simple, standard protocol. Journal of Clinical Microbiology2015;54(4):1324‐30. [PUBMED: 25673797] ">Lau 2015</a>; <a href="./references#CD004920-bbs2-0085" title="PittetD , MonodM , SuterPM , FrenkE , AuckenthalerR . Candida colonisation and subsequent infections in critically ill surgical patients. Annals of Surgery1994;220(6):751‐8. [MEDLINE: 7986142] ">Pittet 1994</a>; <a href="./references#CD004920-bbs2-0097" title="VardakasKZ , MichalopoulosA , KiriakidouKG , SiampliEP , SamonisG , FalagasME . Candidaemia: incidence, risk factors, characteristics and outcomes in immunocompetent critically ill patients. Clinical Microbiology and Infection2009;15(3):289‐92. [PUBMED: 19154488] ">Vardakas 2009</a>) and the use of nonabsorbable antifungal has been recently studied as a measure for risk reduction (<a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>). We defined nonabsorbable antifungal as a drug administered enterally (e.g. orally or through a nasogastric tube) with a topical antifungal effect and no systemic absorption. </p> <p>The study groups were required to differ only for the antifungal regimen under investigation; other co‐interventions and aspects of care, including the routine use of other antimicrobial agents, were required to be the same to avoid potentially confounded comparisons. </p> <p>We excluded studies not reporting the molecule of the antifungal drug used and if this information was not obtained after contacting the authors of the studies. </p> </section> <section id="CD004920-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD004920-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD004920-list-0001"> <li> <p>Total (all‐cause) mortality.</p> </li> <li> <p>Proven invasive fungal infection. The criteria for proven IFI included a clinical illness consistent with the diagnosis and either histopathological evidence of IFI or a positive fungal culture from one or more sterile site specimens (including blood). Positive culture of <i>Candida spp</i>. from the respiratory tract, even in presence of systemic or respiratory signs of infections, was classified as colonization instead of IFI. Funguria (as indicated by a positive urine fungal culture), in the absence of a complicated urinary tract infection, and fungal oesophagitis were classified as superficial fungal infections. </p> </li> </ol> </p> </section> <section id="CD004920-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD004920-list-0002"> <li> <p>Proven or suspected invasive fungal infection. This outcome measure incorporated both proven IFI cases (defined above) and suspected IFI cases (defined as the initiation of systemic antifungal therapy without the fulfilment of the criteria for a proven IFI) in trials that reported both outcomes. </p> </li> <li> <p>Suspected invasive fungal infection. Suspected invasive fungal infections were defined as the initiation of systemic antifungal therapy without the fulfilment of the criteria for a proven IFI. </p> </li> <li> <p>Superficial fungal infection. Superficial fungal infections were defined as superficial cutaneous, oropharyngeal, oesophageal or uncomplicated urinary tract fungal infections. </p> </li> <li> <p>Fungal colonization. Fungal colonization was defined as a positive fungal culture from a single participant in at least one body site that either developed (if not present at baseline) or persisted (if present at baseline) during untargeted antifungal treatment. </p> </li> <li> <p>Proven invasive fungal infection caused by an azole‐resistant <i>Candida</i> species (defined as <i>Candida glabrata</i> , <i>Candida krusei</i> , or another species with documented azole resistance) or a filamentous fungus (such as <i>Aspergillus</i> species). Note: although newer azole antifungal agents (such as voriconazole and posaconazole) have activity against these fungal pathogens, we used the term azole‐resistant <i>Candida spp</i>. to denote fluconazole/ketoconazole resistance. This outcome was already considered in the original review (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>). We decided to analyse it from studies investigating the use of azoles as intervention drug. </p> </li> <li> <p>Fungal colonization with azole‐resistant <i>Candida</i> species. This outcome was already considered in the original review (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>). We decided to analyse it from studies investigating the use of azoles as intervention drug. </p> </li> <li> <p>Adverse events requiring cessation of study drug(s).</p> </li> </ol> </p> <p>We analysed description of clinical and laboratory data provided in each study and we categorized the events according to the definitions above regardless of study authors' classification. Where insufficient information was available to classify events, we contacted study authors for clarification. </p> <p>The time point of assessment of outcome measures was at the time of discharge from ICU or at the end of untargeted treatment, whichever was longer. </p> </section> </section> </section> <section id="CD004920-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004920-sec-0038"> <h4 class="title">Electronic searches</h4> <p>For the original review (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>), the authors searched the Cochrane Central Register of Controlled Trials (CENTRAL, 2005, Issue 3), MEDLINE (OVID: 1966 to 2 September 2005), EMBASE (OVID: 1980 to week 36, 2005). </p> <p>For this updated review we searched all the above mentioned databases from the previous starting date to February 2015. The search terms used in this updated review are listed in <a href="./appendices#CD004920-sec-0092">Appendix 1</a>. </p> <p>We searched the following databases of ongoing/completed trials using the same search terms included in the search strategy for the main databases: </p> <p> <ol id="CD004920-list-0003"> <li> <p><a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> </p> </li> <li> <p>European Clinical Trials Database (EudraCT)</p> </li> <li> <p>International Clinical Trials Registry Platform (ICTRP)</p> </li> <li> <p>ISRCTN registry</p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (ANZCTR)</p> </li> <li> <p>German Clinical Trials Register (GermanCTR)</p> </li> </ol> </p> <p>We conducted the last search of these databases on 10 April 2015.</p> <p>We did not apply a language restriction.</p> </section> <section id="CD004920-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched the proceedings of major relevant conferences (including, but not limited to: Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society for Microbiology; Infectious Diseases Society of America; European Society of Clinical Microbiology and Infectious Diseases; American Society of Anesthesiologists; European Society of Intensive Care Medicine; Society of Critical Care Medicine; International Symposium on Intensive Care and Emergency Medicine. We searched the reference lists of identified trials and major reviews. We contacted researchers active in the field and primary authors of identified relevant trials for additional published and unpublished trial data. We contacted manufacturers of the study drugs for additional published or unpublished trial data. We accepted letters, abstracts, and unpublished trials to reduce publication bias. If we suspected duplicate publications, we contacted the study authors for clarification and, if confirmed, we used the publication with the longest follow‐up data for the review. We searched these resources until 18 April 2015. </p> </section> </section> <section id="CD004920-sec-0040"> <h3 class="title" id="CD004920-sec-0040">Data collection and analysis</h3> <section id="CD004920-sec-0041"> <h4 class="title">Selection of studies</h4> <p>For this updated review three authors (AC, VR, AM) independently retrieved the search report to identify potentially eligible studies, considering titles and abstracts. The same authors analysed the full texts of potentially eligible articles. </p> <p>Two authors (AC, VR) were responsible for contacting the authors of studies if additional information were required for assessment of eligibility and study quality. When disagreement was encountered about eligibility of studies, it was resolved after discussion and consensus among the three authors who performed the scan (AC, VR, AM) and two additional authors (SMR, AG). </p> </section> <section id="CD004920-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>For this updated review, two authors (AC, VR) designed a data extraction form in order to extract data from studies. All items recommended in Section 7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004920-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>) were addressed in the extraction process (<a href="./appendices#CD004920-sec-0093">Appendix 2</a>). Three authors (AC, VR, AM) independently extracted data from studies. When discrepancies were encountered in the extraction process, it was resolved by consensus among the three authors who extracted the data (AC, VR, AM) and two additional authors (SMR, AG). </p> </section> <section id="CD004920-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three authors (AC, VR, AM) assessed the risk of bias of the included studies using the Cochrane tool for assessing risk of bias, as described in Section 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004920-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). When discrepancies were met, the authors discussed with two additional authors (SMR, AG) to solve by consensus. The domains assessed in each included study were: </p> <p> <ol id="CD004920-list-0004"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>In accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD004920-bbs2-0067" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>), all authors defined by consensus key domains among assessed bias for all outcomes (random sequence generation, allocation concealment, incomplete outcome data). We excluded for the primary analysis the studies presenting high risk of bias in one or more key domains (<a href="./references#CD004920-bbs2-0067" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> </section> <section id="CD004920-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed data using the risk ratio (RR) and 95% confidence intervals (CI). No continuous or time‐to‐event outcome measures were addressed as part of this review. </p> </section> <section id="CD004920-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed data using participants who were individually randomized to each group for each outcome addressed. </p> </section> <section id="CD004920-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain missing data from trial authors. When possible, we extracted data to allow an intention‐to‐treat (ITT) analysis in which all randomly assigned participants were analysed in the groups to which they were originally randomized. We calculated the number of excluded participants and the proportion out of the initial number of randomized participants. When information was not available about an outcome, we did not use imputation and we performed an available case analysis (<a href="./references#CD004920-bbs2-0068" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). </p> </section> <section id="CD004920-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical heterogeneity was addressed considering participants' and treatment characteristics (including drugs, dosage and type of antifungal treatment). Methodologic heterogeneity was assessed by comparing the risk of bias in the included studies. Statistical heterogeneity between trials was assessed by visually examining the funnel plot, using the Chi² test and the I² statistic to assess inconsistency (percentage of variability in effect estimates that is due to heterogeneity rather than to sampling error). A P value less than 0.10 and I² statistic value in excess of 50% were taken as indicative of substantial heterogeneity (<a href="./references#CD004920-bbs2-0069" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011d</a>). </p> </section> <section id="CD004920-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>To determine the presence or absence of reporting bias, we planned to examine funnel plots for meta‐analysis of primary outcomes that included 10 or more studies to determine if they were symmetrical. We did a visual assessment of funnel plots for primary outcomes. </p> </section> <section id="CD004920-sec-0049"> <h4 class="title">Data synthesis</h4> <p><a href="./references#CD004920-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5</a> was used to perform the update of this meta‐analysis. For each outcome, all eligible studies that reported the outcome were included and participants who were treated with an untargeted antifungal treatment with any drug (systemic or nonabsorbable) were compared with those who received placebo, no antifungal or any other antifungal drug (with specified molecule). We pooled the results from different trials using a random‐effects model and compared with a fixed‐effect model in a sensitivity analysis. </p> </section> <section id="CD004920-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Should we have identified adequate numbers of eligible studies (at least two for each subgroup), we planned to conduct the following subgroup analyses for this updated review: </p> <p> <ul id="CD004920-list-0005"> <li> <p>Types of participants (post‐surgical participants ≥ 75% versus &lt; 75%)</p> </li> <li> <p>Fluconazole doses (≥ 400 mg/day and &lt; 400 mg/day)</p> </li> </ul> </p> <p>We performed the following additional subgroup analyses:</p> <p> <ul id="CD004920-list-0006"> <li> <p>Systemic versus non‐absorbable antifungal drug</p> </li> <li> <p>Drugs class (azoles versus echinocandins)</p> </li> <li> <p>Type of treatment (empiric treatment versus prophylaxis)</p> </li> <li> <p>Type of control group (placebo or no intervention)</p> </li> </ul> </p> </section> <section id="CD004920-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>We updated the following sensitivity analyses from the original review:</p> <p> <ul id="CD004920-list-0007"> <li> <p>Random‐effects versus fixed‐effect model</p> </li> <li> <p>Random sequence generation (low risk versus unclear and high risk of bias)</p> </li> <li> <p>Allocation concealment (low risk versus unclear and high risk of bias)</p> </li> <li> <p>Blinding of outcome assessors (low risk versus unclear and high risk of bias)</p> </li> </ul> </p> <p>We additionally performed the following sensitivity analyses:</p> <p> <ul id="CD004920-list-0008"> <li> <p>Risk of bias for key domains (all studies versus unclear and low risk)</p> </li> <li> <p>Incomplete data outcome (low risk versus unclear and high risk)</p> </li> <li> <p>Studies without any high risk of bias.</p> </li> </ul> </p> <section id="CD004920-sec-0052"> <h5 class="title">Summary of findings</h5> <p>We used the GRADE approach to interpret findings (<a href="./references#CD004920-bbs2-0093" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). We used GRADEpro software (<a href="./references#CD004920-bbs2-0062" title="McMaster University. GRADEpro GDT. www.gradepro.org. McMaster University, 2015. ">GRADEpro</a>) to import data from <a href="./references#CD004920-bbs2-0091" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5</a> to create ’Summary of findings’ tables using information on quality of evidence, magnitude of effects of the interventions examined and sums of available data on all important outcomes from each study included in the comparison. The GRADE approach considers ‘quality’ to be a judgement of the extent to which we can be confident that the estimates of effect are correct (<a href="./references#CD004920-bbs2-0093" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). Evidence from randomized controlled studies initially was graded as high and was downgraded by one for serious (or by two for very serious) limitations (risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. We selected the following outcomes for the 'Summary of findings' table: </p> <p> <ol id="CD004920-list-0009"> <li> <p>Total (all‐cause) mortality</p> </li> <li> <p>Proven invasive fungal infection</p> </li> <li> <p>Superficial fungal infection</p> </li> <li> <p>Fungal colonization</p> </li> <li> <p>Adverse events requiring cessation of study drug(s)</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004920-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004920-sec-0053"></div> <section id="CD004920-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD004920-sec-0055"> <h4 class="title">Results of the search</h4> <p>We identified a total of 3725 records from both databases and other sources (3687 through databases search and 38 from other sources). After we removed duplicates, 3281 records were screened from title and abstract. We excluded articles at the title and abstract stage (3230) included studies with a non‐randomized design, with other than untargeted antifungal treatment or studies including an ineligible population. We examined 51 records further for eligibility from full‐texts (<a href="#CD004920-fig-0001">Figure 1</a>). Of these, we excluded a total of 18 articles (<a href="./references#CD004920-sec-0113" title="">Characteristics of excluded studies</a>). The reasons for exclusion were as follows: not randomized design (two studies), ineligible population (three studies), ineligible interventions (10 studies), outcomes not relevant (one study), results not available after contacting investigators and sponsors (two studies). We included 22 studies in the qualitative analysis (<a href="./references#CD004920-sec-0112" title="">Characteristics of included studies</a>). Among them, 12 studies were already included in the original review (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>), and 10 were additionally included in this update. Eleven trials compared the use of fluconazole to placebo or no antifungal treatment. Three trials compared ketoconazole versus placebo. One trial compared anidulafungin with placebo. One trial compared caspofungin to placebo. Two trials compared micafungin to placebo. One trial compared amphotericin B to placebo. Two trials compared nystatin to placebo and one trial compared the effect of clotrimazole, ketoconazole, nystatin and no treatment. </p> <div class="figure" id="CD004920-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD004920-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <p>We also identified two new ongoing studies (<a href="./references#CD004920-sec-0115" title="">Characteristics of ongoing studies</a>); and four studies awaiting classification (<a href="./references#CD004920-sec-0114" title="">Characteristics of studies awaiting classification</a>). </p> <p>We included 19 studies in the quantitative analysis for mortality. We excluded one study due to no data about this outcome (<a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>); and one study for high risk of bias for key domains (<a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>). Another study was excluded for the outcome of mortality due to both ineligible outcome data and for high risk of bias for key domains (<a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>). </p> <p>We included 17 studies in the quantitative analysis for proven IFI. Three studies were excluded because data were not available for this outcome (<a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>); and two other studies because of high risk of bias for key domains (<a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>; <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>). </p> </section> <section id="CD004920-sec-0056"> <h4 class="title">Included studies</h4> <p>We included 22 randomized studies in this updated review (See <a href="./references#CD004920-sec-0112" title="">Characteristics of included studies</a>). The total number of participants was 2761. </p> <p><a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a> included 119 participants at least 14 years of age, admitted to a single ICU in the United States either with a diagnosis of trauma or who had undergone intra‐abdominal or intrathoracic surgery. Furthermore, participants were required to have an anticipated length of ICU stay of more than 48 hours and at least one manifest risk factor within 48 hours of ICU admission (central venous catheter placement, administration of total parenteral nutrition, artificial ventilation for more than 24 hours, or treatment with broad‐spectrum antibiotics). Baseline characteristics reported in the analysis included mean age (46 in the treatment group, 42 in the placebo group), sex (82 men and 37 women) and mean acute physiology and chronic health evaluation (APACHE) II score (18 in both groups). Participants were randomized to receive either fluconazole (800 mg initially followed by 400 mg daily intravenously, orally, or enterally) or placebo (given by same route of administration) for the duration of ICU stay. This study was supported by an investigator‐initiated grant from Roerig/Pfizer. </p> <p><a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a> included 61 adult people admitted to five ICUs in Canada for at least 96 hours who developed a clinically suspected ventilator‐associated pneumonia (VAP) after 48 hours of mechanical ventilation. Participants were included if a respiratory tract secretion culture was positive for <i>Candida spp</i> . Respiratory tract specimens were collected within 24 hours of suspicion of infection. Baseline characteristics reported in the analysis included mean age (57.6 in the intervention group, 63 years in the placebo group), sex (44 men and 16 women) mean APACHE II score (22.9 in the treatment group, 23 in the placebo group), mean sequential organ failure assessment score (SOFA) score (3.8 in both groups). Participants were randomized to receive either anidulafungin (200 mg intravenously, followed by 100 mg daily for at least 72 hours) or matching placebo. When <i>Candida spp</i>. were sensitive to fluconazole, participants were de‐escalated to fluconazole or matching placebo. Participants were treated for a total of 14 days. The study was halted prematurely because of difficulty in recruiting participants and diminishing study resources. Sources of support for this study came from Physicians' Services Incorporated Foundation and Pfizer. </p> <p>The ARDS Network trial included 234 people aged at least 18 years admitted to 24 ICUs in the United States, who were ventilated and who developed acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) from direct and indirect lung injury (<a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>). Reported baseline characteristics included mean age (55 in the treatment group, 52 in the placebo group), sex (140 men and 94 women), mean APACHE III score (81.6 in the treatment group, 81 in the placebo group). Participants were randomized to receive either ketoconazole (400 mg daily enterally) or placebo for 21 days or until more than 48 hours of unassisted ventilation was achieved. This study tested the efficacy of ketoconazole in reducing mortality and morbidity in people with ARDS based on its anti‐inflammatory activity. Thus, this study did not test the direct antifungal activity of ketoconazole. This study was supported by National Institute of Health/National Heart, Lung, and Blood Institute contracts (United States). </p> <p><a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a> included 75 adult people admitted to a single ICU in Egypt who were mechanically ventilated for at least 48 hours and expected to remain so for at least an additional 72 hours. Participants were randomized into three groups: group I, who did not receive any prophylactic medication; group II, who received selective digestive decontamination (SDD) consisting of oral decontamination by chlorhexidine, gastrointestinal tract decontamination by oral colistin, respiratory tract decontamination by cefotaxime; group III who received fluconazole (200 mg on the first day, then 100 mg orally, once a day) in addition to SDD until initiation of systemic antifungals according to cultures results or ICU discharge. Reported baseline characteristics included mean age (50.9 in group I, 51.9 in group II, 48.5 in group III), sex (40 men and 35 women), and mean APACHE II score (26 in both group I and II, 27 in group III). </p> <p><a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a> included 49 people at least 16 years of age admitted to two ICUs in Switzerland, with recent abdominal surgery and who had recurrent gastrointestinal perforation or anastomotic leakages that were either suspected or confirmed by surgery. Reported baseline characteristics reported in the analysis included median age (63 years in the treatment group and 57 in the placebo group), sex (28 men and 15 women), median APACHE II score (13 in both treatment and placebo groups). Participants were randomized to receive either fluconazole (400 mg daily intravenously) or placebo until complete resolution of the intra‐abdominal disease. The study was halted prematurely due to slow recruitment. This study was supported in part by a grant from Pfizer. </p> <p><a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a> included 220 people over 18 years of age admitted to a single ICU in Switzerland for surgical or medical reasons or trauma. Participants were mechanically ventilated for at least 48 hours and expected to remain so for an additional 72 hours. All participants received selective decontamination of the digestive tract with oral polymyxin B, neomycin, and vancomycin. Baseline characteristics reported in the analysis included mean age (52.9 years in the treatment group, 55.9 years in the placebo group), sex (140 men and 64 women), mean APACHE II score (20.9 in the treatment group, 21.3 in the placebo group). Participants were randomized to receive fluconazole (100 mg daily intravenously) or placebo until withdrawal from mechanical ventilation. The study was supported by an unrestricted grant by Pfizer. </p> <p><a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a> included 128 people over 18 years of age, admitted to a single ICU in Italy for surgical reasons or trauma, who were mechanically ventilated for more than 48 hours. Baseline characteristics reported in the analysis included mean age (54 years in the treatment group and 58 years in the control group), sex (61 men and 38 women), mean APACHE II score (19.5 in the treatment group, 19.3 in the control group), mean SOFA score (seven in both treatment and control groups). Participants were randomized to receive either nystatin prophylaxis (2 x 10<sup>6</sup> unit three times daily via the nasogastric tube) or no nystatin prophylaxis as control. </p> <p><a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a> included 70 people admitted to a single hospital in China with pancreatitis according to the Pancreas Surgery Group of the Chinese Medical Association 1997 diagnostic criteria (<a href="./references#CD004920-bbs2-0082" title="Pancreatic Group, Chinese Medical Association. Clinical diagnosis and classification standard of acute pancreatitis. Zhonghua Waike Zazhi1997;35:773‐5. ">Pancreatic Group Chinese Medical Association 1997</a>); and at least one predisposing factor for fungal infection (gerontism, diabetes, dysfunction of one or more organ, hyperglycaemia, central venous catheter, total parenteral nutrition, urinary catheterization, surgical operation, gastrointestinal fistula, ICU admission, mechanical ventilation for at least five days, broad‐spectrum antibiotics for at least five days, or super broad‐spectrum antibiotics at least three days). Participants were randomized to receive fluconazole (100 mg daily intravenously), garlicin (120 mg daily intravenously), or neither. Reported baseline characteristics included mean age (48.7 years in the antifungal group, 51.4 in the garlicin group, 50.5 years in the control group), sex (37 men and 33 women) and mean APACHE II score (13.2 in the antifungal group, 11.8 in the garlicin group, 11.6 in the control group). Participants were randomized to receive fluconazole (100 mg daily intravenously), garlicin (120 mg daily intravenously) or neither. Treatment was continued until relief of predisposing factors. We did not consider the garlicin group for the purpose of this current review. </p> <p><a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a> included 71 people admitted to a single ICU in Saudi Arabia with a diagnosis of septic shock according to criteria established in 1992 by the American College of Chest Physicians/Critical Care Society Consensus Conference within 24 hours of onset, from either intra‐abdominal sepsis or nosocomial pneumonia (<a href="./references#CD004920-bbs2-0052" title="BoneRC , BalkRA , CerraFB , DellingerRP , FeinAM , KnausWA , et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest1992;101(6):1644‐55. [PUBMED: 1303622] ">Bone 1992</a>). Reported baseline characteristics included age distribution (17 participants in both groups were younger than 50 years of age, 16 participants in the treatment group were older than 50 years of age, and 21 participants in the placebo group were older than 50 years of age), sex (40 men and 31 women), mean APACHE II score (18.7 in the treatment group, 18.1 in the placebo group). Participants were randomized to receive either fluconazole (200 mg daily intravenously) or placebo for the duration of the septic shock. </p> <p><a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a> included 51 adult people admitted to a single ICU in France for surgical or medical reasons with at least one serious infection under broad spectrum antibiotic treatment. Reported baseline characteristics included mean age (62 years) and mean acute severity index on admission (14.3 in the intervention group and 13.4 in the control group). Participants were randomized to receive either amphotericin B (2 g/day via nasogastric tube) or placebo. </p> <p><a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a> included 81 adult people aged at least 70 years who underwent gastric cancer surgery in a single hospital in Japan. Participants had a plasma concentration of ß‐D‐glucan equal or higher than 11 pg/ml. Reported baseline characteristics included median age (78 years for both groups), sex (13 men and 13 women), and the International Union Against Cancer tumor‐node‐metastasis (TNM) classification (<a href="./references#CD004920-bbs2-0095" title="SobinLH , GospodarowiczMK , WittekindC . TNM Classification of Malignant Tumours. 7th Edition. Chichester, West Sussex, UK: Wiley, 2009. ">Sobin 2009</a>). Participants were randomized to receive either fluconazole (800 mg daily for the first two days intravenously, followed by 400 mg daily intravenously for the following five days) or no fluconazole. </p> <p><a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>. In this phase three unpublished trial, investigators included 103 people at least 16 years of age. Twenty‐one ICUs in the United States and Canada participated in this study. Participants were included if they had a predicted ICU stay of at least 72 hours and were judged to be at a high risk of developing IFIs based on risk factors (usage of systemic antibiotics, use of total parenteral nutrition, renal failure, fungal colonization). Participants' reported baseline characteristics included mean age (52.8 years in the treatment group and 59.9 in the placebo group), sex (61 men and 41 women), mean APACHE II score (16.4 in treatment group and 19.1 in the placebo group), and mean Marshall score (5.7 in the treatment group and 6.3 in the placebo group) (<a href="./references#CD004920-bbs2-0077" title="MarshallJC , CookDJ , ChristouNV , BernardGR , SprungCL , SibbaldWJ . Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Critical Care Medicine1995;23(10):1638‐52. [PUBMED: 7587228] ">Marshall 1995</a>). Participants were randomized to receive either micafungin (100 mg daily intravenously) or placebo until ICU discharge. The study was discontinued because the sponsor (Astellas Pharma) concluded that many truly high risk participants were receiving antifungal prophylaxis off‐study and consequently they were not enrolled into the study. It was judged that a reversal of this trend was unlikely and that a low incidence of fungal events would continue. </p> <p><a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>. In this phase two unpublished study, investigators included 252 people aged at least 18 years of age, admitted to 53 ICUs in Europe with localized/generalized intra‐abdominal infection either community acquired or of nosocomial origin requiring surgery. Participants' baseline characteristics were not available because although they were initially reported in the unpublished document reporting results, they were subsequently removed. Participants were randomized to receive either micafungin (100 mg daily intravenously) or placebo until recovery of gastrointestinal tract function, confirmation of IFI, administration of an alternative antifungal drug or death. This study was sponsored by Astellas Pharma. </p> <p><a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a> included 116 people at least 18 years of age, admitted to a single ICU in France for surgical or medical reasons or trauma, who were expected to require mechanical ventilation for more than 48 hours. Baseline characteristics reported in the analysis included mean age (59 years in the treatment group and 57 in the control group), sex (65 men and 33 women), mean simplified acute physiology score (SAPS) II score (40 in the treatment group, 39 in the control group). Participants were randomized to receive either nystatin prophylaxis (3 x 10<sup>6</sup> unit daily orally) or no oral nystatin prophylaxis. </p> <p><a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a> included 222 people aged at least 18 years, admitted to 15 ICUs in the United States for at least three days, who were mechanically ventilated, received any broad spectrum antibiotic, had a central venous catheter and presented at least one additional risk factor among parenteral nutrition, dialysis, major surgery, pancreatitis, systemic steroids or other immunosuppressive agents. Reported baseline characteristics for participants receiving the intervention of interest included mean age (57.7 in the treatment group and 55.4 in the placebo group), sex (114 men and 72 women), mean APACHE II score (25.0 in the treatment group and 24.9 in the control group). Participants were randomized to receive either caspofungin (70 mg loading dose, followed by 50 mg daily intravenously) or placebo throughout the ICU stay. In this study, there was a second phase characterized by pre‐emptive therapy for subjects who developed proven or probable IFI. We considered only the prophylactic phase of the trial for the purpose of this review. This study was supported and sponsored by Merck. </p> <p><a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a> included 38 people aged at least 18 years of age admitted to a single ICU in the Czech Republic for surgical or medical reasons. Participants were included within five days of admission. They should have received at least 24 hours of antibiotic therapy and at least 48 hours of mechanical ventilation. Reported baseline characteristics included mean age (46 years in the treatment group and 43 in the control group), mean APACHE II score (23.6 in the treatment group and 22.5 in the control group), mean SOFA score (10.8 in the treatment group and 8.6 in the control group). Participants were randomized to receive either fluconazole (100 mg daily intravenously) or no fluconazole until ICU discharge. </p> <p><a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a> included 260 people admitted to a single surgical ICU in the United States for surgical reasons with an expected length of stay of at least three days. Reported baseline characteristics included median age (63 years in the treatment group and 66 years in the placebo group), sex (130 men and 130 women), median APACHE III score (63 in the treatment group, 65 in the control group). Participants were randomized to receive either fluconazole (800 mg loading then 400 mg daily enterally) or placebo until ICU discharge or initiation of an empiric antifungal treatment. </p> <p><a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a> included 110 adult people with intra‐abdominal perforation or anastomotic leakage from 13 hospitals in Norway. Baseline characteristics reported in the analysis included median age (68 years in the treatment group, 60 years in the placebo group) and sex (52 men and 57 women). Participants were randomized to receive either fluconazole (400 mg intravenously) or placebo as a single dose given in the operating room. The study was terminated prematurely due to slow recruitment. The study was supported by Pfizer which provided bottles containing either 400 mg of fluconazole or placebo. </p> <p><a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a> included 292 people admitted to a single ICU in the United States for more than 48 hours with an expected ICU length of stay of at least 48 hours. Reasons for admission were surgery or trauma. Participants were randomized to receive ketoconazole (200 mg daily enterally), clotrimazole (10 mg three times daily enterally), nystatin (2 million units four times daily enterally), or no antifungal until ICU discharge. Reported baseline characteristics included mean age (54 in the clotrimazole group, 57 in the ketoconazole group, 53 in the nystatin group, 54 in the control group), sex (166 men and 126 women), median APACHE II score (12 in the clotrimazole group, 10 in the ketoconazole group, 12 in the nystatin group, 11 in the control group). </p> <p><a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a> included 270 febrile people aged 18 years or older, admitted to 26 ICUs in United States with a predicted ICU stay of at least 96 consecutive hours and an APACHE II score of at least 16 within 24 hours from admission. All participants had a central venous catheter for at least 24 hours and received broad spectrum antibiotics for at least four days. Baseline characteristics reported in the analysis included mean age (53 in the treatment group and 51 in the placebo group), sex (192 men and 57 women), median APACHE II score (22 in the treated group and 20 in the placebo group). Participants were randomized to receive either fluconazole (800 mg daily intravenously) or placebo for 14 days. The sponsor (Pfizer) monitored the trial, assisted the investigators in protocol development and creation of a case report form, provided the study drug, maintained the database and assisted in analysis. </p> <p><a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a> included 74 people admitted to a single surgical ICU in the United States without fungal colonization and with at least three of the following risk factors: age greater than 40 years, second‐ and third‐degree burns covering greater than 30% of body surface area, antibiotics for more than seven days, three or more antibiotics, severe sepsis unresponsive to antibiotics, diabetes, steroids for more than seven days, acute renal failure, immunosuppressive therapy or chemotherapy, advanced malignancy, total parenteral nutrition, multi trauma, serum glucose greater than 11.1 mmol/L, intra‐abdominal abscess, peritonitis, or severe head injury. Median age was 65 in the treatment group and 59 in the placebo group. Participants colonized with <i>Candida</i> at baseline were excluded from the analysis by the authors. Participants were randomized to receive either ketoconazole (200 mg daily enterally) or placebo for 21 days or until ICU discharge. This study was supported by Janssen Pharmaceutica. </p> <p><a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a> included 54 people with surgical sepsis aged at least 16 years admitted to a single surgical ICU in United States. Reported baseline characteristics included mean age (48 years in the treatment group, 58 in the placebo group), sex (38 men, 16 women), mean APACHE II score (12 in the treatment group, 14 in the placebo group). Participants were randomized to receive either ketoconazole (400 mg daily enterally) or placebo for 21 days or until ICU discharge. The investigators began with a 200 mg daily dose of ketoconazole, also administered enterally, but the dose was doubled after the first five participants were treated because of low serum concentrations of the drug. This study investigated the effect of ketoconazole for preventing ARDS in surgical septic participants basing on its anti‐inflammatory activity. Thus, the antifungal activity of ketoconazole was not tested directly. This study was supported by Janssen Pharmaceutica. </p> <p>In all the studies included in the quantitative analysis, the intervention (any antifungal drug for untargeted treatment, either systemic or nonabsorbable) was compared to placebo or no antifungal. We did not find any study eligible for inclusion in the quantitative analysis comparing the effect of two or more different antifungal drugs or regimens. </p> </section> <section id="CD004920-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 18 studies after the review of full records. (See <a href="./references#CD004920-sec-0113" title="">Characteristics of excluded studies</a>). Two studies were not randomized trials (<a href="./references#CD004920-bbs2-0024" title="AzoulayE , TimsitJF , SouweineB , LegrielS , MaxA , MissetB , et al. Weekly high dose liposomal amphotericin B (L‐AMB) in septic shock patients with multiple candida colonization: AMBIDEX study. Intensive Care Medicine. 22nd Annual Congress of the European Society of Intensive Care Medicine (ESICM). Vienna, Austria., 2011; Vol. 37, issue Suppl 1:S6‐314. [PUBMED: 21905295] ">Azoulay 2011</a>; <a href="./references#CD004920-bbs2-0035" title="NCT00689338 . Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study (ICE). clinicaltrials.gov/ct2/show/NCT006893382008. ">NCT00689338</a>). Three studies were excluded because the population was ineligible (<a href="./references#CD004920-bbs2-0026" title="DaeemDA . Efficacy of prophylactic fluconazole in reducing candidemia in high risk nicu and picu patients. Archives of Disease in Childhood. 4th Congress of the European Academy of Paediatric Societies Istanbul Turkey., 2012; Vol. 97, issue Suppl 2:A380. [EMBASE: 71063264] ">Daeem 2012</a>; <a href="./references#CD004920-bbs2-0029" title="LatifADA , Abdel SultanMH , MohamedHE . Efficacy of Prophylactic Fluconazole in Reducing Candidemia in High Risk NICU and PICU Patients. Life Science Journal2012;9(1):817‐24. [Web of Science: 000306398400118] ">Latif 2012</a>; <a href="./references#CD004920-bbs2-0038" title="RestrepoC , ChaconJ , ManjarresG . Fungal peritonitis in peritoneal dialysis patients: successful prophylaxis with fluconazole, as demonstrated by prospective randomized control trial. Peritoneal Dialysis International2010;30(6):619‐25. [PUBMED: 20634438] ">Restrepo 2010</a>). We excluded 10 studies because the interventions studied were not eligible (<a href="./references#CD004920-bbs2-0023" title="AerdtsSJ , vanDalenR , ClasenerHA , FestenJ , vanLierHJ , VollaardEJ . Antibiotic prophylaxis of respiratory tract infection in mechanically ventilated patients. A prospective, blinded, randomized trial of the effect of a novel regimen. Chest1991;100(3):783‐91. [PUBMED: 1889273] ">Aerdts 1991</a>; <a href="./references#CD004920-bbs2-0025" title="BlairP , RowlandsBJ , LowryK , WebbH , ArmstrongP , SmilieJ . Selective decontamination of the digestive tract: a stratified, randomized, prospective study in a mixed intensive care unit. Surgery1991;110(2):303‐10. [PUBMED: 1650036 ] ">Blair 1991</a>; <a href="./references#CD004920-bbs2-0027" title="DeJongeE , SchultzMJ , Spanjaardl , Bossuyt PM VroomMB , DankertJ , et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet2003;362(9389):1011‐6. [PUBMED: 14522530] ">De Jonge 2003</a>; <a href="./references#CD004920-bbs2-0028" title="HansonKE , PfeifferCD , LeaseED , BalchAH , ZaasAK , PerfectJR , et al. β‐D‐glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One2012;7(8):e42282. [PUBMED: 22879929] ">Hanson 2011</a>; <a href="./references#CD004920-bbs2-0030" title="MilanovSG , GeorgievG , TodorovaV , KozarovL , MilanovM . Efficacy and utility of a protocol for pre‐emptive antimycotic therapy. Critical Care. 30rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium., 2010; Vol. 14, issue Suppl 1:70. [PubMed Central 2934516] ">Milanov 2010</a>; <a href="./references#CD004920-bbs2-0031" title="MilanovS , TodorovaVT , GeorgievG , MilanovM . Empirical versus preemptive antimycotic therapy in terms of outcome benefit. Critical Care. 33rd International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, 2013; Vol. 17, issue Suppl 2:84. [PubMed Cantral 3643104] ">Milanov 2013</a>; <a href="./references#CD004920-bbs2-0034" title="NCT00163111 . A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood. clinicaltrials.gov/ct2/show/NCT001631112005. ">NCT00163111</a>; <a href="./references#CD004920-bbs2-0037" title="NCT01524081 . Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures. clinicaltrials.gov/ct2/show/NCT015240812012. ">NCT01524081</a>; <a href="./references#CD004920-bbs2-0039" title="SorkineP , NagarH , WeinbroumA , SettonA , IsraitelE , ScarlattA , et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Critical Care Medicine1996;24(8):1311‐5. [PUBMED: 8706484] ">Sorkine 1996</a>; <a href="./references#CD004920-bbs2-0040" title="WangDH , GaoXJ , WeiLQ , XiaR , LiQ , PengM , et al. The preemptive treatment of invasive Candida infection with reference of corrected colonization index in critically ill patients: a multicentre, prospective, randomized controlled clinical study. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue2009;21(9):525‐8. [PUBMED: 19751559] ">Wang 2009</a>). One study was excluded since it did not include relevant outcomes (<a href="./references#CD004920-bbs2-0036" title="NCT01045798 . Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK‐0991‐067). clinicaltrials.gov/ct2/show/study/NCT01045798?sect=X73401562010. ">NCT01045798</a>). Two studies were excluded because the results were not available after contacting both study investigators and sponsors (<a href="./references#CD004920-bbs2-0032" title="NCT00095316 . Caspofungin Study for Fungal Infections in Adults in Critical Care Settings. clinicaltrials.gov/ct2/show/NCT000953162004. ">NCT00095316</a>; <a href="./references#CD004920-bbs2-0033" title="NCT00099775 . Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units. clinicaltrials.gov/ct2/show/NCT000997752004. ">NCT00099775</a>). </p> <section id="CD004920-sec-0058"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing studies (see <a href="./references#CD004920-sec-0115" title="">Characteristics of ongoing studies</a>). In one of the ongoing studies, febrile participants aged 18 years or older and suspected of suffering from an IFI are randomized to receive either a step‐down therapy consisting on micafungin followed by fluconazole or fluconazole (or other azoles) monotherapy (<a href="./references#CD004920-bbs2-0045" title="EudraCT number:2012‐003172‐39 . Micafungin‐Deescalation study: Evalutating the rate of breakthrough infections of micafungin followed by fluconazole versus fluconazole (or other azoles) in febrile patients. www.clinicaltrialsregister.eu/ctr‐search/trial/2012‐003172‐39/AT2013. ">Lass‐Flörl 2013</a>). The primary endpoint is the breakthrough of fungal infections. The expected sample size is 190 participants. </p> <p>In another study, adult people admitted to 23 ICUs in France, mechanically ventilated for more than four days with sepsis of unknown origin and with at least one extra‐digestive fungal colonization site and multiple organ failure, are eligible for randomization (<a href="./references#CD004920-bbs2-0046" title="NCT01773876 . Empirical Antifungal Treatment in ICUS (EMPIRICUS). clinicaltrials.gov/ct2/show/NCT017738762012. TimsitJF , AzoulayE , CornetM , GangneuxJP , JullienV , VésinA , et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi‐colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials2013;14:399. [PUBMED: 24261608] ">Timsit 2012</a>). Participants are randomized to receive either micafungin (100 mg daily for 14 days intravenously) or placebo. The primary outcome is survival at 28 days without proven invasive infection and breakthrough fungal infection occurring at least 48 hours after initiation of treatment. The expected sample size is 260 participants. </p> </section> <section id="CD004920-sec-0059"> <h5 class="title">Studies awaiting classification</h5> <p>We classified four studies as awaiting classification (see <a href="./references#CD004920-sec-0114" title="">Characteristics of studies awaiting classification</a>). Two studies were identified through searching trial registries (<a href="./references#CD004920-bbs2-0043" title="ISRCTN40372159 . Effects of digestive decontamination by amphotericine B on Candida colonisation and on the risk of invasive candidiasis in a surgical intensive care unit: a prospective randomised study. www.isrctn.com/ISRCTN403721592002. ">Milesi 2002</a>; <a href="./references#CD004920-bbs2-0044" title="ACTRN12605000596606 . Safety and efficacy of ambisome versus conventional amphotericin B in the treatment of patients with suspected or confirmed mycosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=126050005966062005. ">Whitby 2005</a>). In these cases, we could not know if the results were available. We identified two other studies in which it was not possible to evaluate the eligibility of the population (<a href="./references#CD004920-bbs2-0041" title="ChenZ , YangCL , HeHW , ZengJ . The clinical research of nystatin in prevention of invasive fungal infections in patients on mechanical ventilation in intensive care unit. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2013;25(8):475‐8. [PUBMED: 24021043] ">Chen 2013</a>; <a href="./references#CD004920-bbs2-0042" title="HavlicekK , CervinkaV , SakraL , MotyckaV , MenclK . Preemptive antimycotic treatment in critically ill patients in the Czech Republic. International Surgery2008;93(4):244‐6. [PUBMED: 19731862] HavlícekK , MotyckaV , SákraL , MenclK , NingerV , SafusováL . Preemptive antimycotic therapy in critically ill patients. Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti2003;82(2):67‐71. [PUBMED: 12712902] ">Havlicek 2008</a>). In all cases, we contacted the study authors and searched for other sources to get the necessary information without success. </p> </section> </section> </section> <section id="CD004920-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>Full description of judgements regarding risk of bias can be found in the 'Risk of bias' tables following each study in <a href="./references#CD004920-sec-0112" title="">Characteristics of included studies</a> and in <a href="#CD004920-fig-0002">Figure 2</a> and <a href="#CD004920-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004920-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004920-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004920-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004920-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD004920-sec-0061"> <h4 class="title">Allocation</h4> <p>Adequate random sequence generation was reported in details in six studies (<a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). In four studies a computer‐generated randomization sequence was adopted (<a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). In one study, a randomization table was used (<a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>); and in another study a random number generator was adopted (<a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>). According to the information provided, these trials were judged to have a low risk of bias due to inadequate randomization. In eight studies a description of both method and type of the randomization was partially missing (<a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>). Moreover, in seven studies it was almost completely lacking (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In another study, the description of the randomization process provided by the study authors was not clear enough to permit a judgement (<a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>). These 16 studies were judged to be at unclear risk of selection bias due to inadequate randomization. </p> <p>Regarding allocation concealment, nine studies described robust and appropriate methods (central allocation or randomization done by pharmacy or just after the enrolment of the participant) leading to a low risk of selection bias (<a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). In twelve studies, the information provided was not sufficient to enable us to make a judgement leading to the assignment of an unclear risk of selection bias due to inadequate allocation concealment (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In one study, there was a high risk of inadequate allocation concealment due to a reallocation of already randomized participants presenting specific clinical criteria to the other treatment groups (<a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>). </p> </section> <section id="CD004920-sec-0062"> <h4 class="title">Blinding</h4> <p>Eleven studies provided appropriate detail concerning blinding of personnel and outcome assessors and were judged to be at low risk of bias in these domains (<a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). In two studies blinding of personnel was adequate but it was not clear if the outcome assessors were blinded (<a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>). Six studies did not report enough information about blinding; they were also judged at unclear risk of both performance and detection bias (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In one study there was a high risk of inadequate blinding of personnel and a low risk of detection bias due to blinding of outcome assessors (<a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>). In the study by <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a> there was a high risk of inadequate blinding of personnel and it was also unclear if the outcome assessors were blinded to treatment assignment. In the study by <a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a> blinding of personnel and outcome assessors was lacking, leading to a high risk of both performance and detection bias. </p> </section> <section id="CD004920-sec-0063"> <h4 class="title">Incomplete outcome data</h4> <p>In 10 studies no missing outcome data were observed leading to a low risk of bias (<a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In seven studies missing data were balanced in numbers across groups and a low risk of bias was then attributed (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). In one study there was no description of data about participants who had been initially randomized but died or were discharged before the end of the study period (<a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>). Even though the authors pre‐specified the exclusion of participants who would have not completed the study period, we believe this could have biased the results due to a high risk of incomplete outcome data. </p> <p>In one study missing data were unlikely to be related to true outcome, leading to a low risk of bias (<a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>). In one study reasons for exclusion of participants were pre‐specified and they were excluded retrospectively; for this reason we attributed a low risk of attrition bias (<a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). In one study insufficient information to establish the potential risk of incomplete outcome data were provided, leading to an unclear risk of bias (<a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>). In another study authors did not provide sufficient information on whether the exclusion of eight participants happened before or after the randomization and we assigned an unclear risk of bias for this reason (<a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>). </p> </section> <section id="CD004920-sec-0064"> <h4 class="title">Selective reporting</h4> <p>In four studies the protocol was available and all pre‐specified outcomes were reported (<a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>). In 17 studies a protocol was not available but the published reports included all the expected outcomes (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In one study an outcome described in the protocol was not reported in the results and we assigned a high risk of reporting bias for this reason (<a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>). </p> </section> <section id="CD004920-sec-0065"> <h4 class="title">Other potential sources of bias</h4> <p>In 19 studies no other potential sources of bias were detected leading to a low risk of other bias (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In one study, participants received the intervention on admission to ICU although the inclusion criteria stated the need for at least 48 hours of mechanical ventilation for inclusion; thus, there seems to be unclear relationships between inclusion, randomization, allocation concealment and timing of treatment (<a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>). In one study a sample size of 600 participants was originally planned; however, after a data review, a low incidence of fungal endpoints was observed due to a low recruitment rate (<a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>). This was attributed to the off‐study administration of antifungals to truly high risk participants in the participating centres and the study was terminated. After consensus, we decided to consider this study at high risk of other bias for this reason. In another study, participants with altered liver function were not allocated in one treatment group (ketoconazole) leading to a potential unbalanced allocation of most critically ill people (<a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>). </p> </section> </section> <section id="CD004920-sec-0066"> <h3 class="title" id="CD004920-sec-0066">Effects of interventions</h3> <p>See: <a href="./full#CD004920-tbl-0001"><b>Summary of findings for the main comparison</b> Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal in non‐neutropenic critically ill patients</a> </p> <section id="CD004920-sec-0067"> <h4 class="title">Primary outcomes</h4> <section id="CD004920-sec-0068"> <h5 class="title">1. Total (all‐cause) mortality</h5> <p>(See <a href="./references#CD004920-fig-0007" title="">Analysis 1.1</a>) </p> <p>The mortality analysis involved 2374 participants from 19 studies (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). Of these participants 1186 were allocated to the untargeted antifungal treatment group and 1188 to the placebo/no antifungal/any other antifungal group. Overall, 564/2374 (23.8%) died during the study period, 274/1186 (23.1%) in the treatment group and 290/1188 (24.4%) in the other group. This difference was not statistically significant. The risk ratio (RR) of dying if allocated to the untargeted antifungal treatment group compared to the other group was 0.93 (95% CI 0.79 to 1.09, P value = 0.36, I² statistic = 16%). There is no statistically significant difference in the treatment effect on mortality according to the drug used in the treatment group (<a href="#CD004920-fig-0004">Figure 4</a>). The funnel plot for this outcome was symmetrical. The quality of evidence was moderate because most of the studies contributing to this outcome had an overall unclear risk of bias. </p> <div class="figure" id="CD004920-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Untargeted treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.1 Mortality." data-id="CD004920-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Untargeted treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.1 Mortality. </p> </div> </div> </div> </section> <section id="CD004920-sec-0069"> <h5 class="title">2. Proven invasive fungal infection</h5> <p>(See <a href="./references#CD004920-fig-0008" title="">Analysis 1.2</a>) </p> <p>This outcome involved 2024 participants from 17 studies, 1009 allocated to the untargeted antifungal group and 1015 in the other group (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). In total, 162 proven IFI were reported, 57 (35.2 %) in the treatment group and 105 (64.8 %) in the other group. The risk of developing a proven IFI if allocated to the untargeted antifungal treatment group compared to other group was statistically significantly reduced, with a RR of 0.57 (95% CI 0.39 to 0.83, P value = 0.003, I² statistic = 27%). </p> <p>According to the drug used for the untargeted treatment, a statistically significant effect was observed for fluconazole (RR 0.45, 95% CI 0.30 to 0.68; studies = 10, P value = 0.0001, I² statistic = 0%) and for caspofungin in the only study included investigating its use (RR 0.12, 95% CI 0.02 to 0.97; P value = 0.05) (<a href="#CD004920-fig-0005">Figure 5</a>). For this outcome, the test for subgroup difference, according to the drug used, was significant (P value = 0.04, I² statistic = 60.1%). </p> <div class="figure" id="CD004920-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection" data-id="CD004920-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection </p> </div> </div> </div> <p>The quality of evidence was low due to the unclear risk of bias of the contributing studies and the potential for publication bias detected through the observation of asymmetry of the funnel plot (<a href="#CD004920-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD004920-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection." data-id="CD004920-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection. </p> </div> </div> </div> </section> </section> <section id="CD004920-sec-0070"> <h4 class="title">Secondary outcomes</h4> <section id="CD004920-sec-0071"> <h5 class="title">1. Proven or suspected invasive fungal infection</h5> <p>(See <a href="./references#CD004920-fig-0009" title="">Analysis 1.3</a>) </p> <p>Five studies reported this outcome with a total of 911 participants (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). Fifty‐three proven or suspected IFI were reported in the untargeted antifungal treatment group and 84 in the other group. The RR of developing proven or suspected IFI in the treatment group compared to the other group was 0.63 (95% CI 0.39 to 1.00; P value = 0.05, I² statistic = 45%). </p> </section> <section id="CD004920-sec-0072"> <h5 class="title">2. Suspected fungal infection</h5> <p>(See <a href="./references#CD004920-fig-0010" title="">Analysis 1.4</a>) </p> <p>Five studies reported this outcome including 911 participants, 462 in the treatment group and 449 in the control group (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>). A total of 68 suspected fungal infections were observed, 33 in the untargeted antifungal treatment group and 35 in the other group. The risk of developing a suspected fungal infection was not statistically significant with a RR of 0.94 (95% CI 0.38 to 2.32; P value = 0.89). There was a significant statistical heterogeneity across studies reporting this outcome (I² statistic = 43%). The quality of evidence for this outcome was low. All the five studies contributing to this result had an unclear risk of bias leading to a downgrade. Moreover, the total number of participants and events from studies contributing to this result were less than the number which would be generated for the calculation of the optimal information size. We applied a further downgrading for this reason. </p> </section> <section id="CD004920-sec-0073"> <h5 class="title">3. Superficial fungal infection</h5> <p>(See <a href="./references#CD004920-fig-0011" title="">Analysis 1.5</a>) </p> <p>Five studies reported this outcome with a total of 38 events from 662 participants (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>). Fifteen superficial fungal infections occurred in the 331 participants treated with the untargeted antifungal treatment and 23 occurred in the other group including 331 participants. The risk of developing a superficial fungal infection was not statistically significantly different between the two groups (RR 0.69, 95% CI 0.37 to 1.29; P value = 0.24, I² statistic = 0%). </p> </section> <section id="CD004920-sec-0074"> <h5 class="title">4. Fungal colonization</h5> <p>(See <a href="./references#CD004920-fig-0012" title="">Analysis 1.6</a>) </p> <p>Twelve studies reported this outcome involving 1030 participants, 510 in the untargeted antifungal treatment group and 520 in the other group (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). In the intervention group, 145 participants developed a fungal colonization in comparison to 204 participants in the other group. The RR of developing fungal colonization if allocated to the untargeted treatment group was 0.71 (95% CI 0.52 to 0.97; P value = 0.03). The quality of evidence was rated as low as all studies that contributed to this result had an unclear risk of bias and a downgrading was applied. Moreover, we observed a significant statistical heterogeneity across studies (I² statistic = 78%) possibly linked to a clinical heterogeneity that could be explained by the adoption of different criteria for detection of colonization (e.g. different numbers of sites or different locations of sites (or both) analysed for fungal cultures). We applied a further downgrading for this reason. </p> </section> <section id="CD004920-sec-0075"> <h5 class="title">5. Proven invasive fungal infection (Azole‐resistant <i>Candida</i> species) </h5> <p>(See <a href="./references#CD004920-fig-0013" title="">Analysis 1.7</a>) </p> <p>Eight studies reported this outcome including 1058 participants globally (524 in the treatment group and 534 in the other group) (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). Five proven IFIs by azole‐resistant <i>Candida</i> species were described in the treatment group in comparison to 12 in the other group. The risk of developing a proven IFI due to azole‐resistant <i>Candida</i> species for participants allocated in the untargeted antifungal treatment group was not statistically significant with a RR of 0.53 (95% CI 0.20 to 1.40; P value = 0.20, I² statistic = 0%) </p> </section> <section id="CD004920-sec-0076"> <h5 class="title">6. Fungal colonization (azole‐resistant Candida species)</h5> <p>(See <a href="./references#CD004920-fig-0014" title="">Analysis 1.8</a>) </p> <p>Five studies reported this outcome including 409 participants, 203 in the untargeted antifungal treatment group and 206 in the other group (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). Twenty‐one participants colonized by azole‐resistant <i>Candida</i> species were reported, nine in the treatment group and 12 in the control group. The RR of developing a fungal colonization by azole‐resistant <i>Candida</i> species was 1.03 (95% CI 0.34 to 3.12; P value = 0.95, I² statistic = 21%). </p> </section> <section id="CD004920-sec-0077"> <h5 class="title">7. Adverse events requiring cessation of study drug(s)</h5> <p>(See <a href="./references#CD004920-fig-0015" title="">Analysis 1.9</a>) </p> <p>Eleven studies reported adverse events requiring cessation of the treatment, enrolling globally 1691 participants (853 in the untargeted antifungal treatment group and 838 in the other group) (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>). A total of 109 events were reported, 51 in the treatment group and 58 in the other group. The RR of developing an adverse event requiring cessation of treatment if receiving an untargeted antifungal treatment was 0.89 (95% CI 0.62 to 1.27, P value = 0.51, I² statistic = 0%). We did not identify a statistically significant difference among the different drugs studied. The overall quality of evidence was low. We downgraded by one level for the unclear risk of bias of most studies contributing to this outcome. We further downgraded by another level due to the low number of total participants and events compared to the optimal information size. </p> </section> </section> <section id="CD004920-sec-0078"> <h4 class="title">Subgroup analysis</h4> <p>We conducted subgroup analysis assessing mortality and proven invasive fungal infection.</p> <p>In subgroup analyses based on type of participants, the effect of untargeted treatment in studies with 75% or more of post‐surgical participants was not statistically significantly different between the two groups for mortality (RR 0.81, 95% CI 0.60 to 1.08; <a href="./references#CD004920-fig-0016" title="">Analysis 2.1</a>.1; studies = seven, <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>), but significantly different for proven IFI (RR 0.57, 95% CI 0.33 to 0.99; <a href="./references#CD004920-fig-0022" title="">Analysis 2.7</a>.1; studies = six, <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). Concerning studies with fewer than 75% of post‐surgical participants, the risk was not statistically significantly different between groups for both mortality (RR 1.00, 95% CI 0.78 to 1.28; <a href="./references#CD004920-fig-0016" title="">Analysis 2.1</a>.2; studies = 10, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>) and proven IFI (RR 0.57, 95% CI 0.29 to 1.15; <a href="./references#CD004920-fig-0022" title="">Analysis 2.7</a>.2; studies = nine, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). </p> <p>In the subgroup analysis for total fluconazole daily dose of 400 mg or more used as untargeted treatment, the mortality risk was not statistically significantly different between groups (RR 0.95, 95% CI 0.68 to 1.33; <a href="./references#CD004920-fig-0017" title="">Analysis 2.2</a>.1; studies = six, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>); whereas the risk of developing proven IFI was statistically significantly different (RR 0.51, 95% CI 0.32 to 0.79; <a href="./references#CD004920-fig-0023" title="">Analysis 2.8</a>.1; studies = six, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). Concerning studies investigating a total daily dose of fluconazole of less than 400 mg, the risk for mortality was not statistically significantly different between groups (RR 0.82, 95% CI 0.33 to 2.03; <a href="./references#CD004920-fig-0017" title="">Analysis 2.2</a>.2; studies = three, <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>); whereas a statistically significant difference was noticed for proven IFI (RR 0.29, 95% CI 0.12 to 0.72; <a href="./references#CD004920-fig-0023" title="">Analysis 2.8</a>.2; studies = four, <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>). </p> <p>In the subgroup analysis for studies using systemic drugs, there was a statistically insignificant difference between the two groups for mortality (RR 0.91, 95% CI 0.76 to 1.11; <a href="./references#CD004920-fig-0018" title="">Analysis 2.3</a>.1; studies = 16, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>); but a significant difference for the risk of proven IFI (RR 0.52, 95% CI 0.37 to 0.73; <a href="./references#CD004920-fig-0024" title="">Analysis 2.9</a>.1; studies = 14, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). Concerning the use of nonabsorbable drugs (nystatin and enteral amphotericin B) as antifungal for untargeted treatment, there was a statistically insignificant difference e between the two groups both for mortality risk (RR 0.94, 95% CI 0.62 to 1.41; <a href="./references#CD004920-fig-0018" title="">Analysis 2.3</a>.2; studies = three, <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>) and for proven IFI risk (RR 1.24, 95% CI 0.64 to 2.39; <a href="./references#CD004920-fig-0024" title="">Analysis 2.9</a>.2; studies = three, <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>). Comparing the effect of systemic and nonabsorbable drugs, we obtained a statistically significant test for subgroup difference for proven IFI (P value = 0.02; I² statistic = 80.9%; <a href="./references#CD004920-fig-0024" title="">Analysis 2.9</a>). </p> <p>In the subgroup analysis based on drug class, the effect of azole (fluconazole and ketoconazole) as untargeted treatment was not statistically significantly different between two groups for mortality (RR 0.84, 95% CI 0.67 to 1.07; <a href="./references#CD004920-fig-0019" title="">Analysis 2.4</a>.1; studies = 12, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>) but statistically significantly different for proven IFI (RR 0.44, 95% CI 0.30 to 0.66; <a href="./references#CD004920-fig-0025" title="">Analysis 2.10</a>.1; studies = 11, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). The effect of echinocandins (caspofungin, micafungin, anidulafungin) was not statistically significantly different between groups for both mortality (RR 1.12, 95% CI 0.82 to 1.54; <a href="./references#CD004920-fig-0019" title="">Analysis 2.4</a>.2; studies = four, <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>) and proven IFI (RR 0.42, 95% CI 0.07 to 2.46; <a href="./references#CD004920-fig-0025" title="">Analysis 2.10</a>.2; studies = three, <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>). </p> <p>In the subgroup analysis for type of intervention, we evaluated the effect of prophylaxis and empiric treatment. Concerning the use of antifungal prophylaxis, there was no difference between the two groups for mortality (RR 0.92, 95% CI 0.78 to 1.09; <a href="./references#CD004920-fig-0020" title="">Analysis 2.5</a>.1; studies = 12, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a><a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>); but a statistically significant difference for proven IFI (RR 0.39, 95% CI 0.26 to 0.60; <a href="./references#CD004920-fig-0026" title="">Analysis 2.11</a>.1; studies = 12, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). The effect of the empiric treatment was not statistically significantly different between groups for both mortality (RR 0.90, 95% CI 0.57 to 1.44; <a href="./references#CD004920-fig-0020" title="">Analysis 2.5</a>.2; studies = 6, <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>) and proven IFI (RR 1.03, 95% CI 0.67 to 1.60; <a href="./references#CD004920-fig-0026" title="">Analysis 2.11</a>.2; studies = 4, <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). Comparing the effect of prophylaxis and empiric treatment, we calculated a statistically significant test for subgroup difference for proven IFI (P value = 0.002; I² statistic = 89.6%; <a href="./references#CD004920-fig-0026" title="">Analysis 2.11</a>). </p> <p>In the subgroup analysis for type of control group, we assessed the effect of the intervention in studies having either placebo or no intervention as control group. Concerning studies having placebo as control group, there was no statistically significant difference between the two groups for mortality (RR 0.93, 95% CI 0.78 to 1.11; <a href="./references#CD004920-fig-0021" title="">Analysis 2.6</a>.1; studies = 15, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>), but a statistically significant difference for proven IFI (RR 0.59, 95% CI 0.39 to 0.87; <a href="./references#CD004920-fig-0027" title="">Analysis 2.12</a>.1; studies = 12; <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). Concerning studies having no intervention as control group, we found a statistically insignificant difference among the two groups for both mortality (RR 0.95, 95% CI 0.52 to 1.74; <a href="./references#CD004920-fig-0021" title="">Analysis 2.6</a>.2; studies = 4, <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>) and proven IFI (RR 0.30, 95% CI 0.07 to 1.28; <a href="./references#CD004920-fig-0027" title="">Analysis 2.12</a>.2; studies = 5, <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>). </p> </section> <section id="CD004920-sec-0079"> <h4 class="title">Sensitivity analysis</h4> <p>We evaluated mortality and proven IFI in studies using a fixed‐effect model meta‐analysis. Using this model, the risk for mortality remained not statistically significantly different between groups (RR 0.95, 95% CI 0.82 to 1.09; <a href="./references#CD004920-fig-0028" title="">Analysis 3.1</a>; studies = 19, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>); and the risk of developing proven IFI remained statistically significantly different (RR 0.56, 95% CI 0.42 to 0.75; <a href="./references#CD004920-fig-0031" title="">Analysis 3.4</a>; studies = 17, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). </p> <p>We also assessed the risk for both outcomes considering all studies whatever the risk of bias in key domains (random sequence generation, allocation concealment, incomplete data outcome). We obtained a statistically insignificant difference for mortality between groups (RR 0.93, 95% CI 0.80 to 1.08; <a href="./references#CD004920-fig-0029" title="">Analysis 3.2</a>; studies = 20, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>); and a statistically significant difference in risk of developing proven IFI (RR 0.55, 95% CI 0.38 to 0.81; <a href="./references#CD004920-fig-0032" title="">Analysis 3.5</a>; studies = 19, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0004" title="BesheyBN , OkashaAS , EldinMEN . Fluconazole and selective digestive decontamination for prevention of Candida infection in high risk critically ill patients. Alexandria Journal of Medicine2014;50(1):93‐8. [Science Direct S2090506813000572] ">Beshey 2014</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0014" title="NormandS , FrancoisB , DardéML , BouteilleB , BonnivardM , PreuxPM , et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Medicine2005;31(11):1508‐13. [PUBMED: 16195905] ">Normand 2005</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0019" title="SavinoJA , AgarwalN , WryP , PolicastroA , CerabonaT , AustriaL . Routine prophylactic antifungal agents (clotrimazole, ketoconazole, and nystatin) in nontransplant/nonburned critically ill surgical and trauma patients. Journal of Trauma‐Injury Infection &amp; Critical Care1994;36(1):20‐5. [PUBMED: 8295245] ">Savino 1994</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>). </p> <p>We analysed the risk for both outcomes considering only studies without any high risk of bias for key domains. The risk of mortality remained not statistically different (RR 0.94, 95% CI 0.79 to 1.12; <a href="./references#CD004920-fig-0030" title="">Analysis 3.3</a>; studies = 17, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0002" title="AlbertM , WilliamsonD , MuscedereJ , LauzierF , RotsteinC , KanjiS , et al. Candida in the respiratory tract secretions of critically ill patients and the impact of antifungal treatment: a randomized placebo controlled pilot trial (CANTREAT study). Intensive Care Medicine2014;40(9):1313‐22. [PUBMED: 24981955] ">Albert 2014</a>; <a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>; <a href="./references#CD004920-bbs2-0021" title="SlotmanGJ , BurchardKW . Ketoconazole prevents Candida sepsis in critically ill surgical patients. Archives of Surgery1987;122(2):147‐51. [MEDLINE: 3545141] SlotmanGJ , BurchardKW , D'ArezzoA , GannDS . Ketoconazole prevents acute respiratory failure in critically ill surgical patients. The Journal of Trauma1988;28(5):648‐54. [MEDLINE: 3285017] ">Slotman 1987</a>; <a href="./references#CD004920-bbs2-0022" title="YuM , TomasaG . A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Critical Care Medicine1993;21(11):1635‐42. [PUBMED: 8222677] ">Yu 1993</a>), whereas the risk of developing a proven IFI remained statistically different between groups (RR 0.59, 95% CI 0.40 to 0.88; <a href="./references#CD004920-fig-0033" title="">Analysis 3.6</a>; studies = 14, <a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0005" title="EggimannP , FrancioliP , BilleJ , SchneiderR , WuMM , ChapuisG , et al. Fluconazole prophylaxis prevents intra‐abdominal candidiasis in high‐risk surgical patients. Critical Care Medicine1999;27(6):1066‐72. [PUBMED: 10397206] ">Eggimann 1999</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0007" title="GiglioM , CaggianoG , DalfinoL , BrienzaN , AlicinoI , SgobioA , et al. Oral nystatin prophylaxis in surgical/trauma ICU patients: a randomized clinical trial. Critical Care2012;16(2):R57. [PUBMED: 22490643] ">Giglio 2012</a>; <a href="./references#CD004920-bbs2-0008" title="HeYM , LvXS , AiZL , LiuZS , QianQ , SunQ , et al. Prevention and therapy of fungal infection in severe acute pancreatitis: A prospective clinical study. World Journal of Gastroenterology2003;9(11):2619‐21. [PUBMED: 14606111] ">He 2003</a>; <a href="./references#CD004920-bbs2-0009" title="JacobsS , Price EvansDA , TariqM , Al OmarNF . Fluconazole improves survival in septic shock: a randomized double‐blind prospective study. Critical Care Medicine2003;31(7):1938‐46. [MEDLINE: 12847386] ">Jacobs 2003</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>; <a href="./references#CD004920-bbs2-0015" title="Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG‐01: A Multicenter, Randomized, Double‐Blind, Placebo Controlled Trial of Caspofungin (CAS) Prophylaxis vs Placebo Followed by Pre‐Emptive Therapy for Invasive Candidiasis (IC) in High‐Risk Adults in the Critical Care Setting. Preliminary Results. Proceedings of the Annual meeting of the Society for Healthcare epidemiology of America; 2011 Apr 1‐4; Dallas, Texas. 2011. Ostrosky‐ZeichnerL , ShohamS , VazquezJ , ReboliA , BettsR , BarronMA , et al. MSG01: A randomized, double‐blind, placebo‐controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high‐risk adults in the critical care setting. Clinical Infectious Diseases2014;58(9):1219‐26. [PUBMED: 24550378] ">Ostrosky‐Zeichner 2014</a>; <a href="./references#CD004920-bbs2-0016" title="ParizkovaR , CernyV , DostalP , TruhlarA . The effect of prophylactic fluconazole administration on fungal infection in critically ill patients. Anesteziologie a neodkladna pece2000;11(6):271‐5. [EMBASE: 2001046296] ParizkovaR , DostalP , CernyV . Fluconazole prophylaxis of systemic candida infection in non‐neutropenic critically ill patients: a prospective randomized study. Critical Care1999;3(Suppl 1):P061. [PUBMED: PMC3301764] ">Parizkova 2000</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>; <a href="./references#CD004920-bbs2-0018" title="SandvenP , QvistH , SkovlundE , GierckskyKE , NORGAS Group and the Norwegian Yeast Study. Significance of Candida recovered from intraoperative specimens in patients with intra‐abdominal perforations. Critical Care Medicine2002;30(3):541‐7. [PUBMED: 11990912] ">Sandven 2002</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). </p> <p>We also assessed the risk for mortality and proven IFI between groups considering studies with low versus unclear and high risk of bias in random sequence generation, allocation concealment, incomplete data outcome, blinding of outcome assessment. We reported the results in an additional table (see <a href="#CD004920-tbl-0002">Table 1</a>). </p> <div class="table" id="CD004920-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other sensitivity analyses</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome. Name of sensitivity analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Statistical methods</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect Estimate</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Random sequence generation: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>807</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Random Sequence Generation: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1909</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 [0.71, 1.06]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Allocation concealment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1313</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 [0.70, 1.12]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Allocation concealment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1403</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97, [0.78‐1.20]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Blinding of outcome assessment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1943</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 [0.85, 1.16]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Blinding of outcome assessment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>773</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 [0.51, 1.19]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Incomplete data outcome: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2309</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 [0.78. 1.08]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Incomplete data outcome: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>357</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 [0.48, 1.82]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Random sequence generation: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>508</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 [0.43, 1.45]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Random Sequence Generation: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1566</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 [0.28, 0.70]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Allocation concealment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1068</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 [0.28, 0.68]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Allocation concealment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1298</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 [0.32, 1.11]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Blinding of outcome assessment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1395</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 [0.35, 0.87]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Blinding of outcome assessment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 [0.22, 0.74]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Incomplete data outcome: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 [0.35, 0.79</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Incomplete data outcome: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 [0.21, 1.28]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval</p> <p>IFI = invasive fungal infection</p> <p>M‐H = Mantel‐Haenszel</p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004920-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004920-sec-0080"></div> <section id="CD004920-sec-0081"> <h3 class="title" id="CD004920-sec-0081">Summary of main results</h3> <p>The effect estimates for main outcomes are detailed in <a href="./full#CD004920-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We found moderate quality evidence from 19 studies (2374 participants) that the use of untargeted antifungal treatment in non‐neutropenic critically ill patients was not associated with significant survival benefits since it did not significantly reduce or increase total (all‐cause) mortality. Evidence from 17 studies in 2014 people showed that untargeted antifungal treatment may significantly reduce the incidence of invasive fungal infections (IFIs). The quality of evidence for this outcome was low. We found low‐quality evidence that untargeted antifungal treatment may significantly reduce fungal colonization whereas it did not significantly reduce the incidence of superficial fungal infections. Moreover, we found low quality evidence, from 11 studies, supporting that there is no increase in the risk of adverse events requiring cessation of antifungal treatment. Evidence from included studies showed that the use of untargeted antifungal treatment did not significantly reduce or increase the incidence of IFIs by azole‐resistant <i>Candida</i> species, fungal colonization by azole‐resistant <i>Candida</i> species and suspected IFIs. The use of untargeted antifungal treatment did not significantly reduce the incidence of proven or suspected IFIs. </p> </section> <section id="CD004920-sec-0082"> <h3 class="title" id="CD004920-sec-0082">Overall completeness and applicability of evidence</h3> <p>The findings of this review need to be interpreted in light of the following considerations. Firstly, there is a lack of eligible high‐quality randomized controlled trials addressing our outcomes of interest. Only two trials were judged to have an overall low risk of bias (<a href="./references#CD004920-bbs2-0003" title="ARDS Network Authors. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA2000;283(15):1995‐2002. [PUBMED: 10789668] ">ARDS Network 2000</a>; <a href="./references#CD004920-bbs2-0020" title="SchusterMG , EdwardsJEJr , SobelJD , DarouicheRO , KarchmerAW , HadleyS , et al. Empirical Fluconazole versus Placebo for Intensive Care Unit PatientsA Randomized Trial. Annals of Internal Medicine2008;149(2):83‐90. [PUBMED: 18626047] ">Schuster 2008</a>). Secondly, the overall effect of untargeted antifungal treatment came from studies investigating the use of different antifungal drugs covering a wide period of research. The effect of an untargeted antifungal treatment may be influenced by the type of drug used, due to fungal microbiological epidemiology and patterns of resistance to antimicrobials in different ICUs and hospitals (<a href="./references#CD004920-bbs2-0071" title="KettDH , AzoulayE , EcheverriaPM , VincentJL , EPIC II Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Critical Care Medicine2011;39(4):665‐70. [PUBMED: 21169817] ">Kett 2011</a>; <a href="./references#CD004920-bbs2-0084" title="PfallerMA , MoetGJ , MesserSA , JonesRN , CastanheiraM . Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). Journal of Clinical Microbiology2011;49(1):396‐9. [PUBMED: 21068282] ">Pfaller 2011</a>). There was a predominence of studies investigating the use of fluconazole (and azoles in general). Other drugs were tested in few studies. The subgroup analyses, investigating the effects of azoles, echinocandins, systemic and nonabsorbable drugs separately, aimed to deal with this issue (see <a href="./references#CD004920-fig-0018" title="">Analysis 2.3</a>; <a href="./references#CD004920-fig-0019" title="">Analysis 2.4</a>; <a href="./references#CD004920-fig-0024" title="">Analysis 2.9</a>; <a href="./references#CD004920-fig-0025" title="">Analysis 2.10</a>). On the other hand, the participants included in this review seem to be representative of the general population of non‐neutropenic critically ill people, due to the relatively high number of participants for both primary outcomes, different clinical characteristics and severity of illness, and the wide range of geographic locations of enrolling centres. </p> </section> <section id="CD004920-sec-0083"> <h3 class="title" id="CD004920-sec-0083">Quality of the evidence</h3> <p>The quality of the evidence contributing to the main outcomes is described in the <a href="./full#CD004920-tbl-0001">summary of findings Table for the main comparison</a>. The overall quality of evidence contributing to the effect estimate for mortality was considered of moderate grade since most studies that contributed to this outcome had an unclear risk of bias and the quality of evidence was downgraded for this reason. For the outcome of proven IFI, the quality of evidence was rated low due to the unclear risk of bias of the contributing studies and the potential for publication bias detected through the observation of asymmetry of the funnel plot (<a href="#CD004920-fig-0006">Figure 6</a>). A low quality of evidence was also attributed to the outcome of superficial fungal infection, since all five studies contributing to this result had an unclear risk of bias and downgrading was applied (<a href="./references#CD004920-bbs2-0001" title="AblesAZ , BlumerNA , ValainisGT , GodenickMT , KajdaszDK , PaleschYY . Fluconazole prophylaxis of severe candida infection in trauma and postsurgical patients: A prospective, double‐blind, randomized, placebo‐controlled trial. Infectious Diseases in Clinical Practice2000;9(4):169‐75. [EMBASE: 2000158943] ">Ables 2000</a>; <a href="./references#CD004920-bbs2-0006" title="GarbinoJ , LewD , RomandJA , AuckenthalerP , SuterP , PittetD . Fluconazole prevents severe Candida spp infections in high‐risk critically ill patients. A randomized, double‐blind, placebo‐controlled study. 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September–1 October. Washington: American Society for Microbiology, 1997:Abstract LM‐23b. GarbinoJ , LewDP , RomandJA , HugonenetS , AuckenthalerR , PittetD . Prevention of severe Candida infections in nonneutropenic, high‐risk, critically ill patients: a randomized, double‐blind, placebo‐controlled trial in patients treated by selective digestive decontamination. Intensive Care Medicine2002;28(12):1708‐17. [PUBMED: 12447512] ">Garbino 2002</a>; <a href="./references#CD004920-bbs2-0010" title="LeonA , ToubasD , RenardP , SuinatJL , RaclotP , CoussonJ , et al. Diagnosis and prevention of candidosis in the intensive care unit [Diagnostic et prévention des candidoses en réanimation]. Agressologie1990;31(8):514‐8. [PUBMED: 2089973] ">Leon 1990</a>; <a href="./references#CD004920-bbs2-0011" title="NamikawaT , KitagawaH , YamatsujiT , NaomotoY , KobayashiM , HanazakiK . Pre‐emptive treatment of fungal infection based on plasma β‐D‐glucan levels after gastric surgery for gastric cancer in elderly patients. Journal of Gastroenterology and Hepatology2013;28(9):1457‐61. [PUBMED: 23574148] ">Namikawa 2013</a>; <a href="./references#CD004920-bbs2-0017" title="PelzRK , HendrixCW , SwobodaSM , Diener‐WestM , MerzWG , HammondJ , et al. Double‐blind placebo‐controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Annals of Surgery2001;233(4):542‐8. [PUBMED: 11303137] ">Pelz 2001</a>). Moreover, the total number of participants and events from studies contributing to the outcome of superficial fungal infection was less than the number which would be generated for the calculation of the optimal information size: a further downgrading was applied for this reason. For the outcome of fungal colonization, the quality of evidence was rated as low as all studies that contributed to this result had an unclear risk of bias: a downgrading was applied. Moreover, a significant statistical heterogeneity across studies was observed. A clinical heterogeneity across studies investigating the outcome of fungal colonization may be explained by the adoption of different criteria for detection of colonization (e.g. different numbers of sites or different locations of sites (or both) analysed for fungal cultures); we applied a further downgrading for this reason. Regarding the outcome of adverse events requiring cessation of study drug, the overall quality of evidence was low. We downgraded by one level for the unclear risk of bias of most studies contributing to this outcome. We further downgraded by another level due to the low number of total participants and events compared to the optimal information size. </p> </section> <section id="CD004920-sec-0084"> <h3 class="title" id="CD004920-sec-0084">Potential biases in the review process</h3> <p>An unrestricted comprehensive literature search was conducted for both the original and the updated review aiming to minimize reporting and selection bias. We searched clinical trial registries from which we retrieved eligible studies with partial missing data (e.g. part of results and participants characteristics) (<a href="./references#CD004920-bbs2-0012" title="NCT00048750 . A phase 3, randomized, double‐blind comparative study of micafungin (FK 463) versus placebo as preemptive prophylactic antifungal therapy in patients in the intensive care unit. clinicaltrials.gov/ct2/show/NCT000487502002. ">NCT00048750</a>; <a href="./references#CD004920-bbs2-0013" title="NCT01122368 . A Study to evaluate preemptive treatment of Invasive Candidiasis in high risk surgical subjects (INTENSE). clinicaltrials.gov/ct2/show/NCT011223682010. ">NCT01122368</a>). A reconsideration of these studies should be taken into account in light of their possible future peer‐reviewed publication. As part of our search strategy, we contacted study authors, sponsors and pharmaceutical companies of studies reported as ongoing, or completed, but without published results. Moreover, we tried to obtain further information from authors of already published studies in cases of doubt about data. However, on some occasions we had incomplete correspondence. We also had incomplete correspondence regarding the studies awaiting classification (<a href="./references#CD004920-bbs2-0041" title="ChenZ , YangCL , HeHW , ZengJ . The clinical research of nystatin in prevention of invasive fungal infections in patients on mechanical ventilation in intensive care unit. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2013;25(8):475‐8. [PUBMED: 24021043] ">Chen 2013</a>; <a href="./references#CD004920-bbs2-0042" title="HavlicekK , CervinkaV , SakraL , MotyckaV , MenclK . Preemptive antimycotic treatment in critically ill patients in the Czech Republic. International Surgery2008;93(4):244‐6. [PUBMED: 19731862] HavlícekK , MotyckaV , SákraL , MenclK , NingerV , SafusováL . Preemptive antimycotic therapy in critically ill patients. Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti2003;82(2):67‐71. [PUBMED: 12712902] ">Havlicek 2008</a>; <a href="./references#CD004920-bbs2-0043" title="ISRCTN40372159 . Effects of digestive decontamination by amphotericine B on Candida colonisation and on the risk of invasive candidiasis in a surgical intensive care unit: a prospective randomised study. www.isrctn.com/ISRCTN403721592002. ">Milesi 2002</a>; <a href="./references#CD004920-bbs2-0044" title="ACTRN12605000596606 . Safety and efficacy of ambisome versus conventional amphotericin B in the treatment of patients with suspected or confirmed mycosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=126050005966062005. ">Whitby 2005</a>). In two studies we could not ascertain the proportion of included patients with neutropenia even though results were available (<a href="./references#CD004920-bbs2-0041" title="ChenZ , YangCL , HeHW , ZengJ . The clinical research of nystatin in prevention of invasive fungal infections in patients on mechanical ventilation in intensive care unit. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue2013;25(8):475‐8. [PUBMED: 24021043] ">Chen 2013</a>; <a href="./references#CD004920-bbs2-0042" title="HavlicekK , CervinkaV , SakraL , MotyckaV , MenclK . Preemptive antimycotic treatment in critically ill patients in the Czech Republic. International Surgery2008;93(4):244‐6. [PUBMED: 19731862] HavlícekK , MotyckaV , SákraL , MenclK , NingerV , SafusováL . Preemptive antimycotic therapy in critically ill patients. Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti2003;82(2):67‐71. [PUBMED: 12712902] ">Havlicek 2008</a>). We decided not to include these studies in order to avoid potential bias in the review process. In the other two studies we could not obtain necessary further information and results (<a href="./references#CD004920-bbs2-0043" title="ISRCTN40372159 . Effects of digestive decontamination by amphotericine B on Candida colonisation and on the risk of invasive candidiasis in a surgical intensive care unit: a prospective randomised study. www.isrctn.com/ISRCTN403721592002. ">Milesi 2002</a>; <a href="./references#CD004920-bbs2-0044" title="ACTRN12605000596606 . Safety and efficacy of ambisome versus conventional amphotericin B in the treatment of patients with suspected or confirmed mycosis. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=126050005966062005. ">Whitby 2005</a>). </p> <p>In some studies reporting fungal colonization, the outcome did not fit our definition (e.g. studies reporting number of colonized sites by fungi per participants or colonization index). Where possible, we obtained data suitable for our analysis from study authors upon request. However, when the number of participants with at least one colonized site was not available (see <a href="#CD004920-sec-0034">Types of outcome measures</a>), this outcome was not considered for the quantitative analysis. </p> <p>For each included study, we provided a definition for the type of untargeted antifungal treatment used (i.e. prophylactic, pre‐emptive, empiric treatment) according to international guidelines (<a href="./references#CD004920-bbs2-0053" title="CornelyOA , BassettiM , CalandraT , GarbinoJ , KullbergBJ , LortholaryO . ESCMID guideline for the diagnosis and management of Candida diseases 2012: non‐neutropenic adult patients. Clinical Microbiology and Infection2012;18 Suppl 7:19‐37. [PUBMED: 23137135] ">Cornely 2012</a>). However, due to incomplete description of participants' characteristics and settings, this definition attribution was not always straightforward. It may be argued that the intervention studied in this review (untargeted antifungal treatment) encompassed three different treatment strategies possibly leading to heterogeneity. However, it should be considered that all three different antifungal strategies are used before the definitive proof of fungal infections and that is the reason why they are studied as a single intervention in both the original and updated review (<a href="./references#CD004920-bbs2-0103" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004920.pub2] ">Playford 2006a</a>). These aspects should be considered by the reader when considering the results of the subgroup analysis according to the type of treatment. </p> </section> <section id="CD004920-sec-0085"> <h3 class="title" id="CD004920-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews studied the use of antifungal treatment for prevention of IFIs (<a href="./references#CD004920-bbs2-0054" title="CrucianiM , deLallaF , MengoliC . Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta‐analysis. Intensive Care Medicine2005;31(11):1479‐87. [PUBMED: 16172847] ">Cruciani 2005</a>; <a href="./references#CD004920-bbs2-0070" title="HoKM , LipmanJ , DobbGJ , WebbSA . The use of prophylactic fluconazole in immunocompetent high‐risk surgical patients: a meta‐analysis. Critical Care2005;9:R710‐7. [PUBMED: 16280069 ] ">Ho 2005</a>; <a href="./references#CD004920-bbs2-0094" title="SchorrAF , ChungK , JacksonWL , WatermanPE , KollefMH . Fluconazole prophylaxis in critically‐ill surgical patients: a meta‐analysis. Critical Care Medicine2005;33(9):1928‐35. [PUBMED: 16148461] ">Shorr 2005</a>; <a href="./references#CD004920-bbs2-0096" title="VardakasKZ , SamonisG , MichalopoulosA , SoteriadesES , FalagasME . Antifungal prophylaxis with azoles in high‐risk surgical intensive care unit patients: a meta‐analysis of randomized, placebo controlled trials. Critical Care Medicine2006;34(4):1216‐24. [MEDLINE: 16484923] ">Vardakas 2006</a>). They all included critically ill surgical participants and most of their evidence was based on the use of azoles for prophylaxis. They showed a significant reduction of IFIs rate with an associated reduction of mortality risk observed only in one meta‐analysis (<a href="./references#CD004920-bbs2-0054" title="CrucianiM , deLallaF , MengoliC . Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta‐analysis. Intensive Care Medicine2005;31(11):1479‐87. [PUBMED: 16172847] ">Cruciani 2005</a>). Of note, the results for IFIs were similar to that observed in subgroup analysis for azoles (see <a href="./references#CD004920-fig-0025" title="">Analysis 2.10</a>). However, our update encompasses a wider range of participants' characteristics (e.g. both medical and surgical critically ill participants) and this should be considered when these results are compared with those from our review. To our knowledge, there are no more recent systematic reviews investigating the use of azoles, echinocandins, nonabsorbable antifungal drugs as untargeted antifungal treatment in non‐neutropenic adult critically ill patients. Systematic reviews on antifungal agents for prevention of fungal infections were conducted in many other settings including: low‐birth weight infants (<a href="./references#CD004920-bbs2-0047" title="AustinN , McGuideW . Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003850.pub4] ">Austin 2013a</a>; <a href="./references#CD004920-bbs2-0048" title="AustinN , DarlowBA , McGuireW . Prophylactic oral/topical non‐absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD003478.pub4] ">Austin 2013b</a>), children (<a href="./references#CD004920-bbs2-0051" title="BlythCC , HaleK , PalasanthiranP , O'BrienT , BennettMH . Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database of Systematic Reviews2010, Issue 2. [DOI: 10.1002/14651858.CD006343.pub2; PUBMED: 20166083] ">Blyth 2010</a>), people affected by cancer (<a href="./references#CD004920-bbs2-0092" title="RobenshtokE , Gafter‐GviliA , GoldbergE , WeinbergerM , YeshurunM , LeiboviciL , et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem‐cell transplantation: systematic review and meta‐analysis. Journal of Clinical Oncology2007;25(34):5471‐89. [MEDLINE: 17909198] ">Robenshtok 2007</a>; <a href="./references#CD004920-bbs2-0063" title="GøtzschePC , JohansenHK . Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD000026.pub2] ">Gøtzsche 2014</a>), solid organ transplant recipients (<a href="./references#CD004920-bbs2-0055" title="CrucianiM , MengoliC , MalenaM , BoscoO , SerpelloniG , GrossiP . Antifungal prophylaxis in liver transplant patients: a systematic review and meta‐analysis. Liver Transplantation2006;12(5):850‐8. [PUBMED: 16628697] ">Cruciani 2006</a>; <a href="./references#CD004920-bbs2-0076" title="MarinoE , GallagherJC . Prophylactic antifungal agents used after lung transplantation. The Annals of Pharmacotherapy2010;44(3):546‐56. [PUBMED: 20179260] ">Marino 2010</a>; <a href="./references#CD004920-bbs2-0086" title="PlayfordEG , WebsterAC , SorrellTC , CraigJC . Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004291.pub2] ">Playford 2004a</a>). In low‐birth weight infants and children the use of antifungal prophylaxis was not associated with a mortality reduction (<a href="./references#CD004920-bbs2-0047" title="AustinN , McGuideW . Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003850.pub4] ">Austin 2013a</a>; <a href="./references#CD004920-bbs2-0048" title="AustinN , DarlowBA , McGuireW . Prophylactic oral/topical non‐absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD003478.pub4] ">Austin 2013b</a>; <a href="./references#CD004920-bbs2-0051" title="BlythCC , HaleK , PalasanthiranP , O'BrienT , BennettMH . Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database of Systematic Reviews2010, Issue 2. [DOI: 10.1002/14651858.CD006343.pub2; PUBMED: 20166083] ">Blyth 2010</a>), whereas a reduction of IFIs was described (<a href="./references#CD004920-bbs2-0047" title="AustinN , McGuideW . Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003850.pub4] ">Austin 2013a</a>; <a href="./references#CD004920-bbs2-0048" title="AustinN , DarlowBA , McGuireW . Prophylactic oral/topical non‐absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD003478.pub4] ">Austin 2013b</a>). In people with cancer or who underwent hematopoietic stem‐cell transplantation, a mortality reduction was observed with antifungal prophylaxis or empiric treatment (<a href="./references#CD004920-bbs2-0063" title="GøtzschePC , JohansenHK . Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD000026.pub2] ">Gøtzsche 2014</a>; <a href="./references#CD004920-bbs2-0092" title="RobenshtokE , Gafter‐GviliA , GoldbergE , WeinbergerM , YeshurunM , LeiboviciL , et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem‐cell transplantation: systematic review and meta‐analysis. Journal of Clinical Oncology2007;25(34):5471‐89. [MEDLINE: 17909198] ">Robenshtok 2007</a>). A reduction of IFIs in people with cancer was observed after the use of amphotericin B, fluconazole and itraconazole but not with the use of ketoconazole or miconazole (<a href="./references#CD004920-bbs2-0063" title="GøtzschePC , JohansenHK . Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD000026.pub2] ">Gøtzsche 2014</a>). In people who underwent liver transplantation, a reduction of IFI, but not of mortality was reported after antifungal prophylaxis (<a href="./references#CD004920-bbs2-0055" title="CrucianiM , MengoliC , MalenaM , BoscoO , SerpelloniG , GrossiP . Antifungal prophylaxis in liver transplant patients: a systematic review and meta‐analysis. Liver Transplantation2006;12(5):850‐8. [PUBMED: 16628697] ">Cruciani 2006</a>). Due to the different settings and people's characteristics, a comparison of these results with those from this update is not feasible. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004920-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD004920-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004920-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004920-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Untargeted treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.1 Mortality." data-id="CD004920-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Untargeted treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection" data-id="CD004920-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection." data-id="CD004920-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal, outcome: 1.2 Proven invasive fungal infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 1 Mortality." data-id="CD004920-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 2 Proven invasive fungal infection." data-id="CD004920-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 2 Proven invasive fungal infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 3 Proven or suspected invasive fungal infection." data-id="CD004920-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 3 Proven or suspected invasive fungal infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 4 Suspected invasive fungal infection." data-id="CD004920-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 4 Suspected invasive fungal infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 5 Superficial fungal infection." data-id="CD004920-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 5 Superficial fungal infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 6 Fungal colonization." data-id="CD004920-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 6 Fungal colonization. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 7 Proven invasive fungal infection (azole‐resistant Candida species)." data-id="CD004920-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 7 Proven invasive fungal infection (azole‐resistant <i>Candida</i> species). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 8 Fungal colonization (azole‐resistant Candida species)." data-id="CD004920-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 8 Fungal colonization (azole‐resistant <i>Candida</i> species). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 9 Adverse events requiring cessation." data-id="CD004920-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug, Outcome 9 Adverse events requiring cessation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 1 Mortality. Types of participants." data-id="CD004920-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 1 Mortality. Types of participants.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 2 Mortality. Fluconazole dose." data-id="CD004920-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 2 Mortality. Fluconazole dose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 3 Mortality. Systemic or non‐absorbable antifungal drug." data-id="CD004920-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 3 Mortality. Systemic or non‐absorbable antifungal drug. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 4 Mortality. Drug class." data-id="CD004920-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 4 Mortality. Drug class.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 5 Mortality. Type of intervention." data-id="CD004920-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 5 Mortality. Type of intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 6 Mortality. Type of control group." data-id="CD004920-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 6 Mortality. Type of control group.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 7 Proven IFI. Type of participants." data-id="CD004920-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 7 Proven IFI. Type of participants.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 8 Proven IFI. Fluconazole dose." data-id="CD004920-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 8 Proven IFI. Fluconazole dose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 9 Proven IFI. Systemic or non‐absorbable antifungal drug." data-id="CD004920-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 9 Proven IFI. Systemic or non‐absorbable antifungal drug. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 10 Proven IFI. Drug class." data-id="CD004920-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 10 Proven IFI. Drug class.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 11 Proven IFI. Type of intervention." data-id="CD004920-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 11 Proven IFI. Type of intervention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analysis, Outcome 12 Proven IFI. Type of control group." data-id="CD004920-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analysis, Outcome 12 Proven IFI. Type of control group.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 1 Mortality. Fixed‐effect model meta‐analysis." data-id="CD004920-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 1 Mortality. Fixed‐effect model meta‐analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 2 Mortality. Risk of bias for key domains: all studies." data-id="CD004920-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 2 Mortality. Risk of bias for key domains: all studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 3 Mortality. Studies without any high risk of bias.." data-id="CD004920-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 3 Mortality. Studies without any high risk of bias.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 4 Proven IFI. Fixed‐effect model meta‐analysis." data-id="CD004920-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 4 Proven IFI. Fixed‐effect model meta‐analysis.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 5 Proven IFI. Risk of bias for key domains: all studies." data-id="CD004920-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 5 Proven IFI. Risk of bias for key domains: all studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004920-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/urn:x-wiley:14651858:media:CD004920:CD004920-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_t/tCD004920-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Sensitivity analysis, Outcome 6 Proven IFI. Studies without any high risk of bias." data-id="CD004920-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Sensitivity analysis, Outcome 6 Proven IFI. Studies without any high risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/media/CDSR/CD004920/image_n/nCD004920-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004920-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal in non‐neutropenic critically ill patients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Any untargeted treatment with antifungal drugs (systemic or nonabsorbable) compared to placebo, no antifungal, any other antifungal compared to placebo for preventing fungal infections in non‐neutropenic critically ill patients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> preventing fungal infections in non‐neutropenic critically ill patients<br/> <b>Settings: c</b> ritical care setting<br/> <b>Intervention:</b> untargeted treatment with any antifungal drug (systemic or nonabsorbable)<br/> <b>Comparison:</b> placebo or no antifungal or any other antifungal </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no antifungal or any other antifungal</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Untargeted treatment with any antifungal drug (systemic or nonabsorbable)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Total (all‐cause) mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.93<br/> (0.79 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2374<br/> (19 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>244 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000<br/> (193 to 266) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>207 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/> (163 to 226) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Proven invasive fungal infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.57<br/> (0.39 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2024<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/> (40 to 86) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (10 to 21) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Superficial fungal infection</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.69<br/> (0.37 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>662<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>48 per 1000<br/> (26 to 90) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (11 to 40) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Fungal colonization</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.71<br/> (0.52 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1030<br/> (12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>392 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>279 per 1000<br/> (204 to 381) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000<br/> (97 to 181) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Adverse events requiring cessation of study drug(s)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.89<br/> (0.62 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1691<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (43 to 88) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/> (72 to 148) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Most of studies that contributed to this result had an unclear risk of bias. Downgraded by one level. </p> <p><sup>2</sup>Asymmetry of the funnel plot detected by observation. Downgraded by one level. </p> <p><sup>3</sup>All the five studies that contributed to this result had an unclear risk of bias. Downgraded by one level. </p> <p><sup>4</sup>Total number of patients and events from studies that contributed to this result was less than the number of patients generated for the calculation of optimal information size. Downgraded by one level. </p> <p><sup>5</sup>All the studies that contributed to this result had an unclear risk of bias. Downgraded by one level. </p> <p><sup>6</sup>There was considerable statistical heterogeneity across studies. The use of different criteria for detection of fungal colonization in studies contributing to this result may have led to clinical heterogeneity. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal in non‐neutropenic critically ill patients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD004920-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other sensitivity analyses</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome. Name of sensitivity analysis</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Statistical methods</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect Estimate</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Random sequence generation: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>807</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Random Sequence Generation: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1909</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87 [0.71, 1.06]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Allocation concealment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1313</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 [0.70, 1.12]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Allocation concealment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1403</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.97, [0.78‐1.20]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Blinding of outcome assessment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1943</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 [0.85, 1.16]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Blinding of outcome assessment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>773</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 [0.51, 1.19]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Incomplete data outcome: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2309</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92 [0.78. 1.08]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality. Incomplete data outcome: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>357</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 [0.48, 1.82]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Random sequence generation: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>508</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79 [0.43, 1.45]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Random Sequence Generation: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1566</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 [0.28, 0.70]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Allocation concealment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1068</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44 [0.28, 0.68]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Allocation concealment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1298</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59 [0.32, 1.11]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Blinding of outcome assessment: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1395</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 [0.35, 0.87]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Blinding of outcome assessment: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>920</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41 [0.22, 0.74]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Incomplete data outcome: low risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1966</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 [0.35, 0.79</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proven IFI. Incomplete data outcome: unclear/high risk of bias</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 [0.21, 1.28]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI = confidence interval</p> <p>IFI = invasive fungal infection</p> <p>M‐H = Mantel‐Haenszel</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/full#CD004920-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004920-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.62, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ketoconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Caspofungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.74, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Micafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.65, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Amphotericin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.54, 5.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Nystatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.55, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Anidulafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.42, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proven invasive fungal infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.30, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Ketoconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.03, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Caspofungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Micafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.22, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Nystatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Amphotericin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.64, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Proven or suspected invasive fungal infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.32, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Caspofungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Suspected invasive fungal infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>911</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.38, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.25, 5.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Caspofungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Superficial fungal infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.37, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.29, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Amphotericin B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.9 [0.27, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Fungal colonization <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.52, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.30, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Ketoconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.45, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Micafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Nystatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.46, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Anidalafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.18, 19.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proven invasive fungal infection (azole‐resistant <i>Candida</i> species) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.20, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.20, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Ketoconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fungal colonization (azole‐resistant <i>Candida</i> species) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.34, 3.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.58, 5.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Ketoconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events requiring cessation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1691</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Fluconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Ketoconazole</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.20, 7.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Caspofungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.13, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Micafungin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.60, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Nystatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Primary analysis: untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) compared to placebo/no antifungal/any other antifungal drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004920-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality. Types of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.76, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Post‐surgical patients ≥ 75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.60, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Post‐surgical patients &lt; 75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.78, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality. Fluconazole dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.62, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluconazole dose ≥ 400 mg/die</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fluconazole dose &lt; 400 mg/die</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.33, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality. Systemic or non‐absorbable antifungal drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Non‐absorbable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.62, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality. Drug class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.76, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Azoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.67, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Echinocandins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.82, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality. Type of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Empiric treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.57, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality. Type of control group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Proven IFI. Type of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.40, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Post‐surgical patients ≥ 75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.33, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Post‐surgical patients &lt; 75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.29, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Proven IFI. Fluconazole dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.30, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Fluconazole dose ≥ 400 mg/die</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.32, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Fluconazole dose &lt; 400 mg/die</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Proven IFI. Systemic or non‐absorbable antifungal drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Systemic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Non‐absorbable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.64, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Proven IFI. Drug class <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Azoles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.30, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Echinocandins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.07, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Proven IFI. Type of intervention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.26, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Empiric treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.67, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Proven IFI. Type of control group <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 No intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.07, 1.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004920-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality. Fixed‐effect model meta‐analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2374</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality. Risk of bias for key domains: all studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality. Studies without any high risk of bias. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.79, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Proven IFI. Fixed‐effect model meta‐analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.42, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Proven IFI. Risk of bias for key domains: all studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.38, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Proven IFI. Studies without any high risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.40, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sensitivity analysis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004920.pub3/references#CD004920-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004920.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD004920-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD004920-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004920-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD004920-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD004920-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD004920-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004920-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004920\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004920\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004920\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004920\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004920\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004920.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004920.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004920.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004920.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004920.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715442343"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004920.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715442347"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004920.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d872db86f9374',t:'MTc0MDcxNTQ0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 